[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"_public_publisher_byId_1838f536-7f53-4427-ad9a-d68f448a64c1":3,"_public_publication_all{\"sortAscending\":false,\"sortField\":\"updateTime\",\"page\":0,\"size\":10,\"facet\":true,\"searchKey\":\"publisherId:1838f536-7f53-4427-ad9a-d68f448a64c1,\"}":157},{"code":4,"data":5,"meta":18},"SUCCESS",{"id":6,"createTime":7,"updateTime":8,"relativeEntities":9,"slug":10,"properties":11,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":20,"manageAffiliations":45,"indexDatabases":68,"url":18,"thumbnailPath":18,"statistic":109,"gsStatistic":18,"type":18,"analyzePriority":18},"1838f536-7f53-4427-ad9a-d68f448a64c1","2024-04-06T05:47:08.118+00:00","2025-11-21T10:06:06.137+00:00",[],"Drug-Metabolism-and-Pharmacokinetics",{"issn":12,"title":14},{"VOID":13},"13474367",{"EN":15},"Drug Metabolism and Pharmacokinetics","PUBLISHER","PENDING",null,0,[21,29,37],{"id":22,"createTime":23,"updateTime":24,"relativeEntities":25,"label":26,"description":28,"parentId":18,"standard":18,"scholarHubFieldId":18},"8b51d244-613f-4ff9-b308-d32de7c33ed9","2023-05-29T10:24:08.511+00:00","2023-11-21T07:37:03.796+00:00",[],{"EN":27},"Pharmacology",{},{"id":30,"createTime":31,"updateTime":32,"relativeEntities":33,"label":34,"description":36,"parentId":18,"standard":18,"scholarHubFieldId":18},"8d3ee16d-8f93-4e34-b94e-cd3a00dde338","2023-05-29T10:24:36.755+00:00","2023-11-21T05:10:53.773+00:00",[],{"EN":35},"Pharmacology (medical)",{},{"id":38,"createTime":39,"updateTime":40,"relativeEntities":41,"label":42,"description":44,"parentId":18,"standard":18,"scholarHubFieldId":18},"988aad6e-c496-4836-b969-f61991a0eed2","2023-05-29T10:24:08.494+00:00","2023-11-21T05:14:42.646+00:00",[],{"EN":43},"Pharmaceutical Science",{},[46,58],{"id":47,"createTime":48,"updateTime":49,"relativeEntities":50,"slug":51,"properties":52,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":56,"url":18,"parentIds":57,"statistic":18},"649632b2-0f5d-4c1f-8c0f-6a4478a87dba","2023-05-29T11:09:56.374+00:00","2024-01-26T09:08:36.608+00:00",[],"Japanese-Society-for-the-Study-of-Xenobiotics",{"title":53},{"EN":54},"Japanese Society for the Study of Xenobiotics","AFFILIATION",2,[],{"id":59,"createTime":60,"updateTime":61,"relativeEntities":62,"slug":63,"properties":64,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":56,"url":18,"parentIds":67,"statistic":18},"287f10b7-bc0a-4e97-a4b0-55dc66510f9d","2023-05-29T12:38:09.924+00:00","2024-01-28T17:32:47.440+00:00",[],"JAPANESE-SOC-STUDY-XENOBIOTICS",{"title":65},{"EN":66},"JAPANESE SOC STUDY XENOBIOTICS",[],[69,88],{"id":70,"indexDatabase":71,"url":85,"indexYears":18,"academicFieldIds":86,"indexDatabaseRanking":18},"c0086c24-8b05-455e-9f7f-fa5061d4aee7",{"id":72,"createTime":73,"updateTime":74,"relativeEntities":75,"label":76,"description":78,"key":81,"publicationTags":82,"standard":18},"a4921856-b128-4d9f-8f1f-e80813d3bbd4","2023-05-22T09:59:31.026+00:00","2025-11-21T10:07:52.153+00:00",[],{"EN":77,"VI":77},"ISI\u002FSCIE - Science Citation Index Expanded",{"VI":79,"EN":80},"Cơ sở dữ liệu SCIE","SCIE database","scie",[83,84],"SCIE","ISI","https:\u002F\u002Fmjl.clarivate.com\u002Fsearch-results?issn=1347-4367",[87],"2b943d65-24a8-4546-9232-a1e32c12cb6c",{"id":89,"indexDatabase":90,"url":102,"indexYears":103,"academicFieldIds":104,"indexDatabaseRanking":108},"e53362d6-0e4f-4fa9-88c3-38f614352fd5",{"id":91,"createTime":92,"updateTime":93,"relativeEntities":94,"label":95,"description":97,"key":99,"publicationTags":100,"standard":18},"3c7051d4-eb7d-4c57-a56b-36fc74c5d1e9","2023-05-22T09:57:18.509+00:00","2025-11-21T10:07:52.274+00:00",[],{"EN":96,"VI":96},"Scopus - Elsevier",{"EN":96,"VI":98},"Cơ sở dữ liệu Scopus thuộc Elsevier","scopus",[101],"SCOPUS","https:\u002F\u002Fwww.scopus.com\u002Fsourceid\u002F144956","2002-2025",[105,106,107],"6e740848-171b-4f21-8d03-9fed10ed0384","46eddd1f-e049-4237-8609-9d60083086ad","e39d1b91-b03d-48ed-87bb-ab5b714ad558","SCOPUS__Q1",{"impactFactor":19,"impactFactorByYear":110,"i10Index":116,"i10IndexLast5Year":19,"totalPublication":117,"totalPublicationByYear":118,"totalCitation":132,"totalCitationByYear":133,"totalCitationPerPublication":145,"totalCitationPerPublicationByYear":146,"hindexLast5Year":116,"hindex":116},{"2012":111,"2013":112,"2014":113,"2015":114,"2019":115},0.12,0.2,0.37,0.28,0.02,13,635,{"2002":119,"2003":120,"2004":121,"2005":121,"2006":122,"2007":119,"2008":119,"2009":123,"2010":124,"2011":124,"2012":125,"2013":126,"2014":127,"2015":123,"2016":124,"2017":128,"2018":129,"2019":129,"2020":127,"2021":125,"2022":130,"2023":131,"2024":56},30,23,24,31,34,33,28,29,40,19,22,25,21,1624,{"2003":134,"2004":135,"2005":136,"2006":137,"2007":138,"2008":139,"2009":140,"2011":141,"2012":142,"2013":143,"2018":144},59,424,342,125,47,14,383,63,44,122,1,2.56,{"2003":147,"2004":148,"2005":149,"2006":150,"2007":151,"2008":152,"2009":153,"2011":154,"2012":151,"2013":155,"2018":156},2.57,17.67,14.25,4.03,1.57,0.47,11.26,1.91,4.21,0.05,{"meta":158,"data":160},{"total":159},"637",[161,290,431,532,678,890,1006,1330,1523,1617],{"id":162,"createTime":163,"updateTime":164,"relativeEntities":165,"slug":166,"properties":167,"entityType":174,"verifyStatus":175,"verifyTime":176,"verifyNote":177,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":178,"fullTextUrl":18,"authors":179,"publicationType":253,"publisherRelationship":254,"citationCount":18,"citationInfo":18,"publishDate":287,"publishYear":288,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":289},"248337c7-5e84-43af-97e2-ad354b4d5a74","2024-02-11T01:27:42.799+00:00","2025-01-08T23:53:59.620+00:00",[],"Versatile-applicability-of-a-grid-based-CYP3A4-Template-to-understand-the-interacting-mechanisms-with-the-small-size-ligands-part-3-of-CYP3A4-Template-study",{"references":168,"title":170,"doi":172},{"VOID":169},"Yamazoe, 2011, Construction of a CYP2E1-template system for prediction of the metabolism on both site and preference order, Drug Metab Rev, 43, 409, 10.3109\u002F03602532.2011.624103\nKoyama, 2011, Development of two-dimensional template system for the prediction of CYP2B6-mediated reaction sites, Drug Metabol Pharmacokinet, 26, 309, 10.2133\u002Fdmpk.DMPK-10-RG-097\nYamaura, 2011, Predicting oxidation sites with order of occurrence among multiple sites for CYP4A-mediated reactions, Drug Metabol Pharmacokinet, 26, 351, 10.2133\u002Fdmpk.DMPK-11-RG-004\nSato, 2012, Unimolecular and bimolecular binding system for the prediction of CYP2D6-mediated metabolism, Drug Metab Dispos, 40, 486, 10.1124\u002Fdmd.111.043125\nYamazoe, 2016, Prediction of regioselectivity and preferred order of metabolisms on CYP1A2-mediated reactions. Part 1. Focusing on polycyclic arenes and the related chemicals, Drug Metabol Pharmacokinet, 31, 363, 10.1016\u002Fj.dmpk.2016.07.005\nYamazoe, 2017, Prediction of regioselectivity and preferred order of metabolisms on CYP1A2-mediated reactions. Part 2: solving substrate interactions of CYP1A2 with non-PAH substrates on the template system, Drug Metabol Pharmacokinet, 32, 229, 10.1016\u002Fj.dmpk.2017.05.004\nYamazoe, 2019, Prediction of regioselectivity and preferred order of metabolisms on CYP1A2-mediated reactions Part 3: difference in substrate specificity of human and rodent CYP1A2 and the refinement of predicting system, Drug Metabol Pharmacokinet, 34, 217, 10.1016\u002Fj.dmpk.2019.02.001\nYamazoe, 2020, Prediction of regioselectivity and preferred order of CYP1A1-mediated metabolism: solving the interaction of human and rat CYP1A1 forms with ligands on the template system, Drug Metabol Pharmacokinet, 10.1016\u002Fj.dmpk.2019.10.008\nYamazoe, 2019, Reconstitution of CYP3A4 active site through assembly of ligand interactions as a grid-template: solving the modes of the metabolism and inhibition, Drug Metabol Pharmacokinet, 34, 113, 10.1016\u002Fj.dmpk.2018.10.001\nGoto, 2019, Solving the interactions of steroidal ligands with CYP3A4 using a grid-base template system, Drug Metabol Pharmacokinet, 34, 351, 10.1016\u002Fj.dmpk.2019.05.003\nWilliams, 2004, Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone, Science, 305, 683, 10.1126\u002Fscience.1099736\nYano, 2004, The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-A resolution, J Biol Chem, 279, 38091, 10.1074\u002Fjbc.C400293200\nShou, 1994, The role of 12 cDNA-expressed human, rodent, and rabbit cytochromes P450 in the metabolism of benzo[a]pyrene and benzo[a]pyrene trans-7,8-dihydrodiol, Mol Carcinog, 10, 159, 10.1002\u002Fmc.2940100307\nBauer, 1995, Oxidation of benzo[a]pyrene by recombinant human cytochrome P450 enzymes, Chem Res Toxicol, 8, 136, 10.1021\u002Ftx00043a018\nSeidel, 1998, Regio- and stereoselectivity in the metabolism of benzo[c]phenanthrene mediated by genetically engineered V79 Chinese hamster cells expressing rat and human cytochromes P450, Environ Toxicol Pharmacol, 5, 179, 10.1016\u002FS1382-6689(97)10073-4\nShou, 1996, Metabolic activation of the potent carcinogen dibenzo[a,h]anthracene by cDNA-expressed human cytochromes P450, Arch Biochem Biophys, 328, 201, 10.1006\u002Fabbi.1996.0161\nKim, 2004, Identification of cytochrome P450 isoforms involved in 1-hydroxylation of pyrene, Environ Res, 94, 262, 10.1016\u002FS0013-9351(03)00134-8\nJushchyshyn, 2005, Catalytic turnover of pyrene by CYP3A4: evidence that cytochrome b5 directly induces positive cooperativity, Arch Biochem Biophys, 438, 21, 10.1016\u002Fj.abb.2005.02.027\nShou, 1994, Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site, Biochemistry, 33, 6450, 10.1021\u002Fbi00187a009\nCho, 2006, In vitro metabolism of naphthalene by human liver microsomal cytochrome P450 enzymes, Drug Metab Dispos, 34, 176, 10.1124\u002Fdmd.105.005785\nRoberts-Thomson, 1995, Metabolism of polycyclic aza-aromatic carcinogens catalyzed by four expressed human cytochromes P450, Canc Res, 55, 1052\nKoehl, 1996, Metabolism of 5-methylchrysene and 6-methylchrysene by human hepatic and pulmonary cytochrome P450 enzymes, Canc Res, 56, 316\nWojcikowski, 2010, Main contribution of the cytochrome P450 isoenzyme 1A2 (CYP1A2) to N-demethylation and 5-sulfoxidation of the phenothiazine neuroleptic chlorpromazine in human liver-A comparison with other phenothiazines, Biochem Pharmacol, 80, 1252, 10.1016\u002Fj.bcp.2010.06.045\nWojcikowski, 2003, Contribution of human cytochrome P-450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine, Br J Pharmacol, 138, 1465, 10.1038\u002Fsj.bjp.0705195\nYoshii, 2000, Identification of human cytochrome P450 isoforms involved in the 7-hydroxylation of chlorpromazine by human liver microsomes, Life Sci, 67, 175, 10.1016\u002FS0024-3205(00)00613-5\nKerr, 1994, Human liver carbamazepine metabolism Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation, Biochem Pharmacol, 47, 1969, 10.1016\u002F0006-2952(94)90071-X\nPearce, 2002, Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites, Drug Metab Dispos, 30, 1170, 10.1124\u002Fdmd.30.11.1170\nEgnell, 2003, In vivo CYP3A4 heteroactivation is a possible mechanism for the drug interaction between felbamate and carbamazepine, J Pharmacol Exp Therapeut, 305, 1251, 10.1124\u002Fjpet.102.047530\nUeng, 1997, Cooperativity in oxidations catalyzed by cytochrome P450 3A4, Biochemistry, 36, 370, 10.1021\u002Fbi962359z\nPearce, 2008, Pathways of carbamazepine bioactivation in vitro. III. The role of human cytochrome P450 enzymes in the formation of 2,3-dihydroxycarbamazepine, Drug Metab Dispos, 36, 1637, 10.1124\u002Fdmd.107.019562\nYue, 1997, Different effects of inhibitors on the O- and N-demethylation of codeine in human liver microsomes, Eur J Clin Pharmacol, 52, 41, 10.1007\u002Fs002280050247\nBocker, 1986, Oxidation of 4-aryl- and 4-alkyl-substituted 2,6-dimethyl-3,5-bis(alkoxycarbonyl)-1,4-dihydropyridines by human liver microsomes and immunochemical evidence for the involvement of a form of cytochrome P-450, J Med Chem, 29, 1596, 10.1021\u002Fjm00159a007\nNiwa, 1988, Stereoselective oxidation and plasma-protein binding of nilvadipine, a new dihydropyridine calcium-antagonist, Res Commun Chem Pathol Pharmacol, 60, 161\nIshiguro, 2000, Identification of CYP3A4 as the predominant isoform responsible for the metabolism of ambroxol in human liver microsomes, Xenobiotica, 30, 71, 10.1080\u002F004982500237839\nKomatsu, 2000, Formation of a dihydroxy metabolite of phenytoin in human liver microsomes\u002Fcytosol: roles of cytochromes P450 2C9, 2C19, and 3A4, Drug Metab Dispos, 28, 1361\nJacobsen, 1999, Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver, Drug Metab Dispos, 27, 173\nIsin, 2007, Multiple sequential steps involved in the binding of inhibitors to cytochrome P450 3A4, J Biol Chem, 282, 6863, 10.1074\u002Fjbc.M610346200\nKim, 2003, alpha-Hydroxylation of tamoxifen and toremifene by human and rat cytochrome P450 3A subfamily enzymes, Chem Res Toxicol, 16, 1138, 10.1021\u002Ftx0300131\nDehal, 1999, Cytochrome P-450 3A and 2D6 catalyze ortho hydroxylation of 4-hydroxytamoxifen and 3-hydroxytamoxifen (droloxifene) yielding tamoxifen catechol: involvement of catechols in covalent binding to hepatic proteins, Drug Metab Dispos, 27, 681\nStresser, 1997, Catalytic characteristics of CYP3A4: requirement for a phenolic function in ortho hydroxylation of estradiol and mono-O-demethylated methoxychlor, Biochemistry, 36, 2203, 10.1021\u002Fbi962129k\nFoster, 1999, Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4, Br J Clin Pharmacol, 47, 403, 10.1046\u002Fj.1365-2125.1999.00921.x\nSullivan, 1973, Urinary metabolites of dl-methadone in maintenance subjects, J Med Chem, 16, 909, 10.1021\u002Fjm00266a009\nDilmaghanian, 2004, Enantioselectivity of inhibition of cytochrome P450 3A4 (CYP3A4) by ketoconazole: testosterone and methadone as substrates, Chirality, 16, 79, 10.1002\u002Fchir.10294\nGiraud, 2004, In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19, Drug Metab Dispos, 32, 1279, 10.1124\u002Fdmd.32.11.1279\nKobayashi, 2004, Pharmacogenetic roles of CYP2C19 and CYP2B6 in the metabolism of R- and S-mephobarbital in humans, Pharmacogenetics, 14, 549, 10.1097\u002F01.fpc.0000114764.78957.22\nYasumori, 1993, Species differences in stereoselective metabolism of mephenytoin by cytochrome P450s (CYP2C and CYP3A), J Pharmacol Exp Therapeut, 264, 89\nAkutsu, 2007, Identification of human cytochrome P450 isozymes involved in diphenhydramine N-demethylation, Drug Metab Dispos, 35, 72, 10.1124\u002Fdmd.106.012088\nHe, 2001, Metabolism of sulfinpyrazone sulfide and sulfinpyrazone by human liver microsomes and cDNA-expressed cytochrome P450s, Drug Metab Dispos, 29, 701\nRamirez, 2004, CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes, Drug Metab Dispos, 32, 930\nLaurenzana, 1997, Metabolism of phencyclidine by human liver microsomes, Drug Metab Dispos, 25, 557\nBenetton, 2007, P450 phenotyping of the metabolism of selegiline to desmethylselegiline and methamphetamine, Drug Metabol Pharmacokinet, 22, 78, 10.2133\u002Fdmpk.22.78\nYun, 1993, Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation, Drug Metab Dispos, 21, 403\nCzerwinski, 1991, Metabolic activation of 4-ipomeanol by complementary DNA-expressed human cytochromes P-450: evidence for species-specific metabolism, Canc Res, 51, 4636\nPerini, 2005, Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam, Clin Pharmacol Ther, 78, 362, 10.1016\u002Fj.clpt.2005.06.014\nRiley, 2001, Development of a generalized, quantitative physicochemical model of CYP3A4 inhibition for use in early drug discovery, Pharm Res, 18, 652, 10.1023\u002FA:1011085411050\nKalgutkar, 2005, Bioactivation of the nontricyclic antidepressant nefazodone to a reactive quinone-imine species in human liver microsomes and recombinant cytochrome P450 3A4, Drug Metab Dispos, 33, 243, 10.1124\u002Fdmd.104.001735\nChesne, 1998, Metabolism of meloxicam in human liver involves cytochromes P4502C9 and 3A4, Xenobiotica, 28, 1, 10.1080\u002F004982598239704\nLudwig, 1999, Activation of human cytochrome P-450 3A4-catalyzed meloxicam 5'-methylhydroxylation by quinidine and hydroquinidine in vitro, J Pharmacol Exp Therapeut, 290, 1\nTaavitsainen, 2001, In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene, Drug Metab Dispos, 29, 217\nRotstein, 1992, Stereoisomers of ketoconazole: preparation and biological activity, J Med Chem, 35, 2818, 10.1021\u002Fjm00093a015\nNakamura, 2005, Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes, Biol Pharm Bull, 28, 882, 10.1248\u002Fbpb.28.882\nKatoh, 2000, Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactionse, Eur J Clin Pharmacol, 55, 843, 10.1007\u002Fs002280050706\nKatoh, 2000, Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P- glycoprotein-mediated transport: comparison with the effects on CYP3A4, Pharm Res, 17, 1189, 10.1023\u002FA:1007568811691\nFoti, 2011, Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction, Drug Metab Dispos, 39, 1188, 10.1124\u002Fdmd.111.038505\nFukuda, 1997, Specific CYP3A4 inhibitors in grapefruit juice: furocoumarin dimers as components of drug interaction, Pharmacogenetics, 7, 391, 10.1097\u002F00008571-199710000-00008\nGuo, 2000, Role of furanocoumarin derivatives on grapefruit juice-mediated inhibition of human CYP3A activity, Drug Metab Dispos, 28, 766\nTassaneeyakul, 2000, Inhibition selectivity of grapefruit juice components on human cytochromes P450, Arch Biochem Biophys, 378, 356, 10.1006\u002Fabbi.2000.1835",{"EN":171},"Versatile applicability of a grid-based CYP3A4 Template to understand the interacting mechanisms with the small-size ligands; part 3 of CYP3A4 Template study",{"VOID":173},"10.1016\u002Fj.dmpk.2020.01.001","PUBLICATION","VERIFIED","2025-01-08T23:53:59.619+00:00","Auto Verify","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS1347436720300021",[180,216,241],{"id":181,"sortIndex":19,"researcher":18,"roles":182,"affiliations":184,"properties":213},"de7962d7-c29f-4063-9e29-d1ab61b63889",[183],"AUTHOR",[185,195,203],{"id":186,"sortIndex":56,"affiliation":187,"properties":194},"2cd5f179-6879-4952-aeaf-83f901da7d07",{"id":188,"createTime":189,"updateTime":189,"relativeEntities":190,"slug":18,"properties":191,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"890f232f-2055-4930-b30f-c143890dcc1a","2023-12-06T18:55:19.954+00:00",[],{"title":192},{"VI":193},"Division of Risk Assessment, National Institute of Health Sciences, Tonomachi 3-25-26, Kawasaki-ku, Kanagawa, 210-9501, Japan",{},{"id":18,"sortIndex":19,"affiliation":196,"properties":18},{"id":197,"createTime":198,"updateTime":198,"relativeEntities":199,"slug":18,"properties":200,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"7773c1df-8a02-49be-a38c-36e8a0694edf","2023-12-01T07:27:16.341+00:00",[],{"title":201},{"VI":202},"Division of Drug Metabolism and Molecular Toxicology, Graduate School of Pharmaceutical Sciences, Tohoku University, 6-3 Aramaki-Aoba, Aoba-ku, Sendai 980-8578, Japan",{"id":204,"sortIndex":144,"affiliation":205,"properties":212},"86edc7af-e1cd-4f9e-bb90-ea62b116eb7b",{"id":206,"createTime":207,"updateTime":207,"relativeEntities":208,"slug":18,"properties":209,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"870e37bb-50b2-4dea-85cd-ec37e31140af","2024-02-11T01:27:42.821+00:00",[],{"title":210},{"VI":211},"Food Safety Commission, Cabinet Office, Government of Japan, Akasaka Park Bldg. 22F 5-2-20 Akasaka, Minato-ku, Tokyo, 107-6122, Japan",{},{"title":214},{"VI":215},"Yasushi Yamazoe",{"id":217,"sortIndex":144,"researcher":18,"roles":218,"affiliations":219,"properties":238},"e46d3f17-7e49-4345-9a7b-dee0dd9c4715",[183],[220,230],{"id":221,"sortIndex":144,"affiliation":222,"properties":229},"852890f2-115e-49a4-b993-01b182982902",{"id":223,"createTime":224,"updateTime":224,"relativeEntities":225,"slug":18,"properties":226,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"717071bb-b55b-400d-a91f-ba9263a836a7","2023-12-06T18:55:19.939+00:00",[],{"title":227},{"VI":228},"Regulatory Science, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1, Tanabe-dori, Mizuho-ku, Nagoya, 467-8603, Japan",{},{"id":18,"sortIndex":19,"affiliation":231,"properties":18},{"id":232,"createTime":233,"updateTime":233,"relativeEntities":234,"slug":18,"properties":235,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"a5909fc6-3137-4341-a8d9-ea87dc696619","2024-02-11T01:27:42.841+00:00",[],{"title":236},{"VI":237},"Essential Medicines and Health Products, Access to Medicines, Vaccines and Pharmaceuticals, World Health Organization, Avenue Appia 20, 1211, Geneva 27, Switzerland",{"title":239},{"VI":240},"Takahiro Goto",{"id":242,"sortIndex":56,"researcher":18,"roles":243,"affiliations":244,"properties":250},"fe14b198-2454-4de9-8d72-f48210f2a7ee",[183],[245],{"id":18,"sortIndex":19,"affiliation":246,"properties":18},{"id":223,"createTime":224,"updateTime":224,"relativeEntities":247,"slug":18,"properties":248,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":249},{"VI":228},{"title":251},{"VI":252},"Masahiro Tohkin","ARTICLE",{"url":178,"publisher":255,"properties":282},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":256,"slug":10,"properties":257,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":260,"manageAffiliations":261,"indexDatabases":262,"url":18,"thumbnailPath":18,"statistic":277,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":258,"title":259},{"VOID":13},{"EN":15},[],[],[263,270],{"id":70,"indexDatabase":264,"url":85,"indexYears":18,"academicFieldIds":269,"indexDatabaseRanking":18},{"id":72,"createTime":73,"updateTime":74,"relativeEntities":265,"label":266,"description":267,"key":81,"publicationTags":268,"standard":18},[],{"EN":77,"VI":77},{"VI":79,"EN":80},[83,84],[87],{"id":89,"indexDatabase":271,"url":102,"indexYears":103,"academicFieldIds":276,"indexDatabaseRanking":108},{"id":91,"createTime":92,"updateTime":93,"relativeEntities":272,"label":273,"description":274,"key":99,"publicationTags":275,"standard":18},[],{"EN":96,"VI":96},{"EN":96,"VI":98},[101],[105,106,107],{"impactFactor":19,"impactFactorByYear":278,"i10Index":116,"i10IndexLast5Year":19,"totalPublication":117,"totalPublicationByYear":279,"totalCitation":132,"totalCitationByYear":280,"totalCitationPerPublication":145,"totalCitationPerPublicationByYear":281,"hindexLast5Year":116,"hindex":116},{"2012":111,"2013":112,"2014":113,"2015":114,"2019":115},{"2002":119,"2003":120,"2004":121,"2005":121,"2006":122,"2007":119,"2008":119,"2009":123,"2010":124,"2011":124,"2012":125,"2013":126,"2014":127,"2015":123,"2016":124,"2017":128,"2018":129,"2019":129,"2020":127,"2021":125,"2022":130,"2023":131,"2024":56},{"2003":134,"2004":135,"2005":136,"2006":137,"2007":138,"2008":139,"2009":140,"2011":141,"2012":142,"2013":143,"2018":144},{"2003":147,"2004":148,"2005":149,"2006":150,"2007":151,"2008":152,"2009":153,"2011":154,"2012":151,"2013":155,"2018":156},{"volume":283,"pages":285},{"VOID":284},"35",{"VOID":286},"253-265","2020-06-01",2020,false,{"id":291,"createTime":292,"updateTime":293,"relativeEntities":294,"slug":295,"properties":296,"entityType":174,"verifyStatus":175,"verifyTime":293,"verifyNote":177,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":303,"fullTextUrl":18,"authors":304,"publicationType":253,"publisherRelationship":396,"citationCount":18,"citationInfo":18,"publishDate":429,"publishYear":430,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":289},"cad3e0fb-ad39-4a8b-a76a-8d1ac870ac24","2023-12-11T03:31:21.867+00:00","2025-02-03T23:52:42.367+00:00",[],"Human-CYP4B1-Gene-in-the-Japanese-Population-Analyzed-by-Denaturing-HPLC",{"references":297,"title":299,"doi":301},{"VOID":298},"Nhamburo, 1989, Identification of a new P450 expressed in human lung: complete cDNA sequence, cDNA-directed expression, and chromosome mapping, Biochemistry, 28, 8060, 10.1021\u002Fbi00446a014\nYokotani, 1990, cDNA cloning of cytochrome P-450 related to P-450p-2 from the cDNA library of human placenta, Eur. J. Biochem., 187, 23, 10.1111\u002Fj.1432-1033.1990.tb15273.x\nImaoka, 2000, CYP4B1 is a possible risk factor for bladder cancer in humans, Biochem. Biophys. Res. Commun., 277, 776, 10.1006\u002Fbbrc.2000.3740\nRobertson, 1983, The relationship between increases in the hepatic content of cytochrome P450, form 5, and in the metabolism of aromatic amines to mutagenic products following treatment of rabbits with Phenobarbital, Mol. Pharmacol., 24, 156\nSmith, 1995, 4-Ipomeanol and 2-aminoanthracene cytotoxicity in C3H\u002F10T1\u002F2 cells expressing rabbit cytochrome P450 4B1, Biochem. Pharmacol., 50, 1567, 10.1016\u002F0006-2952(95)02029-2\nRobertson, 1986, The importance of 2-aminofluorene in the mutagenic activation of 2-acetylaminofluorene, Mutat. Res., 175, 153, 10.1016\u002F0165-7992(86)90115-6\nVanderslice, 1985, The cytochrome P-450 monooxygenase system of rabbit bladder mucosa: enzyme components and isozyme 5-dependent metabolism of 2-aminofluorene, Cancer Res., 45, 5851\nLo-Guidice, 2002, Genetic polymorphism of the human cytochrome P450 CYP4B1: evidence for a non-functional allelic variant, Pharmacogenetics, 12, 367, 10.1097\u002F00008571-200207000-00004\nFrueh, 2003, The use of denaturing high-performance liquid chromatography (DHPLC) for the analysis of genetic variations: impact for diagnostics and pharmacogenetics, Clin. Chem. Lab. Med., 41, 452, 10.1515\u002FCCLM.2003.068\nYu, 1994, Acetylator phenotype, aminobiphenylhemoglobin adduct levels, and bladder cancer risk in white, black, and Asian men in Los Angeles California, J. Natl. Cancer Inst., 86, 712, 10.1093\u002Fjnci\u002F86.9.712",{"EN":300},"Human CYP4B1 Gene in the Japanese Population Analyzed by Denaturing HPLC",{"VOID":302},"10.2133\u002Fdmpk.19.114","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS1347436715308053",[305,321,343,359,371,384],{"id":306,"sortIndex":307,"researcher":18,"roles":308,"affiliations":309,"properties":318},"c36ff2f8-ae0b-4d9f-bcb5-1c2f6934bc38",5,[183],[310],{"id":18,"sortIndex":19,"affiliation":311,"properties":18},{"id":312,"createTime":313,"updateTime":313,"relativeEntities":314,"slug":18,"properties":315,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"469e350a-1532-4b2d-b1d7-88ddb207a48e","2024-02-10T19:52:39.165+00:00",[],{"title":316},{"VI":317},"Department of Clinical Pharmaceutics, Tohoku Pharmaceutical University, Sendai, Japan",{"title":319},{"VI":320},"Michinao Mizugaki",{"id":322,"sortIndex":144,"researcher":18,"roles":323,"affiliations":324,"properties":340},"48ceacb2-f1ec-425c-891e-6077c041d429",[183],[325,330],{"id":18,"sortIndex":19,"affiliation":326,"properties":18},{"id":312,"createTime":313,"updateTime":313,"relativeEntities":327,"slug":18,"properties":328,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":329},{"VI":317},{"id":331,"sortIndex":144,"affiliation":332,"properties":339},"98226423-a562-4b93-b0d5-0b32e0b0e1e5",{"id":333,"createTime":334,"updateTime":334,"relativeEntities":335,"slug":18,"properties":336,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"758d7a22-5dcc-4fe8-b94d-e519ed82e287","2023-12-11T03:31:21.980+00:00",[],{"title":337},{"VI":338},"Department of Pharmacy, NTT East Tohoku Hospital, Sendai, Japan",{},{"title":341},{"VI":342},"Hisayoshi Nozawa",{"id":344,"sortIndex":345,"researcher":18,"roles":346,"affiliations":347,"properties":356},"f6743cfd-03c4-410d-89f1-0af257ed3376",4,[183],[348],{"id":18,"sortIndex":19,"affiliation":349,"properties":18},{"id":350,"createTime":351,"updateTime":351,"relativeEntities":352,"slug":18,"properties":353,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"89c4aaf2-32b9-4a78-89cc-ddb0da60de6c","2023-12-11T03:31:22.087+00:00",[],{"title":354},{"VI":355},"Department of Pharmacy, Hoshi General Hospital, Koriyama, Japan",{"title":357},{"VI":358},"Shoetsu Konno",{"id":360,"sortIndex":19,"researcher":18,"roles":361,"affiliations":362,"properties":368},"52d8951b-5298-476a-a945-2eae624bb15d",[183],[363],{"id":18,"sortIndex":19,"affiliation":364,"properties":18},{"id":312,"createTime":313,"updateTime":313,"relativeEntities":365,"slug":18,"properties":366,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":367},{"VI":317},{"title":369},{"VI":370},"Masahiro Hiratsuka",{"id":372,"sortIndex":373,"researcher":18,"roles":374,"affiliations":375,"properties":381},"2c869e3a-8757-4e7c-99fd-eedc4d7d1963",3,[183],[376],{"id":18,"sortIndex":19,"affiliation":377,"properties":18},{"id":312,"createTime":313,"updateTime":313,"relativeEntities":378,"slug":18,"properties":379,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":380},{"VI":317},{"title":382},{"VI":383},"Tomomi Saito",{"id":385,"sortIndex":56,"researcher":18,"roles":386,"affiliations":387,"properties":393},"d15acd52-8296-4007-aa55-120ec65444d7",[183],[388],{"id":18,"sortIndex":19,"affiliation":389,"properties":18},{"id":312,"createTime":313,"updateTime":313,"relativeEntities":390,"slug":18,"properties":391,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":392},{"VI":317},{"title":394},{"VI":395},"Yumiko Konno",{"url":303,"publisher":397,"properties":424},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":398,"slug":10,"properties":399,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":402,"manageAffiliations":403,"indexDatabases":404,"url":18,"thumbnailPath":18,"statistic":419,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":400,"title":401},{"VOID":13},{"EN":15},[],[],[405,412],{"id":70,"indexDatabase":406,"url":85,"indexYears":18,"academicFieldIds":411,"indexDatabaseRanking":18},{"id":72,"createTime":73,"updateTime":74,"relativeEntities":407,"label":408,"description":409,"key":81,"publicationTags":410,"standard":18},[],{"EN":77,"VI":77},{"VI":79,"EN":80},[83,84],[87],{"id":89,"indexDatabase":413,"url":102,"indexYears":103,"academicFieldIds":418,"indexDatabaseRanking":108},{"id":91,"createTime":92,"updateTime":93,"relativeEntities":414,"label":415,"description":416,"key":99,"publicationTags":417,"standard":18},[],{"EN":96,"VI":96},{"EN":96,"VI":98},[101],[105,106,107],{"impactFactor":19,"impactFactorByYear":420,"i10Index":116,"i10IndexLast5Year":19,"totalPublication":117,"totalPublicationByYear":421,"totalCitation":132,"totalCitationByYear":422,"totalCitationPerPublication":145,"totalCitationPerPublicationByYear":423,"hindexLast5Year":116,"hindex":116},{"2012":111,"2013":112,"2014":113,"2015":114,"2019":115},{"2002":119,"2003":120,"2004":121,"2005":121,"2006":122,"2007":119,"2008":119,"2009":123,"2010":124,"2011":124,"2012":125,"2013":126,"2014":127,"2015":123,"2016":124,"2017":128,"2018":129,"2019":129,"2020":127,"2021":125,"2022":130,"2023":131,"2024":56},{"2003":134,"2004":135,"2005":136,"2006":137,"2007":138,"2008":139,"2009":140,"2011":141,"2012":142,"2013":143,"2018":144},{"2003":147,"2004":148,"2005":149,"2006":150,"2007":151,"2008":152,"2009":153,"2011":154,"2012":151,"2013":155,"2018":156},{"volume":425,"pages":427},{"VOID":426},"19",{"VOID":428},"114-119","2004-01-01",2004,{"id":432,"createTime":433,"updateTime":434,"relativeEntities":435,"slug":436,"properties":437,"entityType":174,"verifyStatus":175,"verifyTime":434,"verifyNote":177,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":56,"primaryUrl":444,"fullTextUrl":18,"authors":445,"publicationType":253,"publisherRelationship":497,"citationCount":18,"citationInfo":18,"publishDate":530,"publishYear":531,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":289},"19bbc1b6-4248-41be-a486-cf09470e14fe","2023-12-06T21:40:34.760+00:00","2025-01-29T23:52:16.655+00:00",[],"Drug-Interaction-Studies-Reveal-That-Simotinib-Upregulates-Intestinal-Absorption-by-Increasing-the-Paracellular-Permeability-of-Intestinal-Epithelial-Cells",{"references":438,"title":440,"doi":442},{"VOID":439},"Herbst, 2004, Review of epidermal growth factor receptor biology, Int. J. Radiat. Oncol. Biol. Phys., 59, 21, 10.1016\u002Fj.ijrobp.2003.11.041\nLevitzki, 2006, Tyrphostins and other tyrosine kinase inhibitors, Annu. Rev. Biochem., 75, 93, 10.1146\u002Fannurev.biochem.75.103004.142657\nHaouala, 2011, Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib, Blood, 117, e75, 10.1182\u002Fblood-2010-07-294330\nTogashi, 2011, Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancer, Lung Cancer, 74, 98, 10.1016\u002Fj.lungcan.2011.01.022\nWardill, 2013, Chemotherapy-induced mucosal barrier dysfunction: an updated review on the role of intestinal tight junctions, Curr. Opin. Support. Palliat. Care, 7, 155, 10.1097\u002FSPC.0b013e32835f3e8c\nGroschwitz, 2009, Intestinal barrier function: molecular regulation and disease pathogenesis, J. Allergy Clin. Immunol., 124, 3, 10.1016\u002Fj.jaci.2009.05.038\nKomarova, 2010, Regulation of endothelial permeability via paracellular and transcellular transport pathways, Annu. Rev. Physiol., 72, 463, 10.1146\u002Fannurev-physiol-021909-135833\nYamamoto, 1997, The Ras target AF-6 interacts with ZO-1 and serves as a peripheral component of tight junctions in epithelial cells, J. Cell Biol., 139, 785, 10.1083\u002Fjcb.139.3.785\nSheth, 2004, Epidermal growth factor prevents acetaldehyde-induced paracellular permeability in Caco-2 cell monolayer, Alcohol. Clin. Exp. Res., 28, 797, 10.1097\u002F01.ALC.0000125358.92335.90\nSingh, 2007, Juxtacrine activation of EGFR regulates claudin expression and increases trans-epithelial resistance, Am. J. Physiol. Cell Physiol., 293, C1660, 10.1152\u002Fajpcell.00274.2007\nBretschneider, 1999, Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+\u002Fpeptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux, Pharm. Res., 16, 55, 10.1023\u002FA:1018814627484\nGanapathy, 1998, Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2, Biochem. Biophys. Res. Commun., 246, 470, 10.1006\u002Fbbrc.1998.8628\nKhan, 2003, Transport of parthenolide across human intestinal cells (Caco-2), Planta Med., 69, 1009, 10.1055\u002Fs-2003-45147\nKrishna, 2001, Permeability of lipophilic compounds in drug discovery using in-vitro human absorption model, Caco-2, Int. J. Pharm., 222, 77, 10.1016\u002FS0378-5173(01)00698-6\nZnalesniak, 2010, Modulation of cell-cell contacts during intestinal restitution in vitro and effects of epidermal growth factor (EGF), Cell. Physiol. Biochem., 25, 533, 10.1159\u002F000303057\nHerbst, 2005, TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer, J. Clin. Oncol., 23, 5892, 10.1200\u002FJCO.2005.02.840\nShepherd, 2005, Erlotinib in previously treated non-small-cell lung cancer, N. Engl. J. Med., 353, 123, 10.1056\u002FNEJMoa050753\nGatzemeier, 2007, Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial, J. Clin. Oncol., 25, 1545, 10.1200\u002FJCO.2005.05.1474\nGiaccone, 2004, Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 1, J. Clin. Oncol., 22, 777, 10.1200\u002FJCO.2004.08.001\nHerbst, 2004, Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial— INTACT 2, J. Clin. Oncol., 22, 785, 10.1200\u002FJCO.2004.07.215\nThatcher, 2005, Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer), Lancet, 366, 1527, 10.1016\u002FS0140-6736(05)67625-8\nKim, 2008, Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial, Lancet, 372, 1809, 10.1016\u002FS0140-6736(08)61758-4\nMiller, 2012, Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b\u002F3 randomised trial, Lancet Oncol., 13, 528, 10.1016\u002FS1470-2045(12)70087-6\nHirsh, 2011, Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer, Curr. Oncol., 18, 126, 10.3747\u002Fco.v18i3.877\nKondoh, 2007, Tight junction modulators: promising candidates for drug delivery, Curr Med. Chem., 14, 2482, 10.2174\u002F092986707782023640\nOoshio, 2010, Involvement of the interaction of afadin with ZO-1 in the formation of tight junctions in Madin-Darby canine kidney cells, J. Biol. Chem., 285, 5003, 10.1074\u002Fjbc.M109.043760\nYokoyama, 2001, α-Catenin-independent recruitment of ZO-1 to nectin-based cell-cell adhesion sites through afadin, Mol. Biol. Cell, 12, 1595, 10.1091\u002Fmbc.12.6.1595\nHare, 2007, The intestinotrophic peptide, glp-2, counteracts intestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, gefitinib, Clin. Cancer Res., 13, 5170, 10.1158\u002F1078-0432.CCR-07-0574\nLee, 2011, Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy, PLoS ONE, 6\nLi, 2006, Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters, Drug Metab. Dispos., 34, 547, 10.1124\u002Fdmd.105.006791",{"EN":441},"Drug Interaction Studies Reveal That Simotinib Upregulates Intestinal Absorption by Increasing the Paracellular Permeability of Intestinal Epithelial Cells",{"VOID":443},"10.2133\u002Fdmpk.dmpk-13-rg-123","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS1347436715303438",[446,461,473,485],{"id":447,"sortIndex":144,"researcher":18,"roles":448,"affiliations":449,"properties":458},"86507110-f350-41f8-8591-46fa7e7d8754",[183],[450],{"id":18,"sortIndex":19,"affiliation":451,"properties":18},{"id":452,"createTime":453,"updateTime":453,"relativeEntities":454,"slug":18,"properties":455,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"21fccab2-b01d-4239-a459-f20d688374e4","2023-12-06T21:40:34.846+00:00",[],{"title":456},{"VI":457},"The School of Pharmaceutical Sciences in Central South University, Changsha, Hunan, China",{"title":459},{"VI":460},"Zhifang Liu",{"id":462,"sortIndex":56,"researcher":18,"roles":463,"affiliations":464,"properties":470},"4e187a20-56d6-4dec-8479-c536bf0f3a85",[183],[465],{"id":18,"sortIndex":19,"affiliation":466,"properties":18},{"id":452,"createTime":453,"updateTime":453,"relativeEntities":467,"slug":18,"properties":468,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":469},{"VI":457},{"title":471},{"VI":472},"Pei Li",{"id":474,"sortIndex":373,"researcher":18,"roles":475,"affiliations":476,"properties":482},"bc019ee6-590a-4a06-adb8-67f6cf890370",[183],[477],{"id":18,"sortIndex":19,"affiliation":478,"properties":18},{"id":452,"createTime":453,"updateTime":453,"relativeEntities":479,"slug":18,"properties":480,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":481},{"VI":457},{"title":483},{"VI":484},"Zeneng Cheng",{"id":486,"sortIndex":19,"researcher":18,"roles":487,"affiliations":488,"properties":494},"1eb908b5-9cc3-40c2-ba00-93293744ff6c",[183],[489],{"id":18,"sortIndex":19,"affiliation":490,"properties":18},{"id":452,"createTime":453,"updateTime":453,"relativeEntities":491,"slug":18,"properties":492,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":493},{"VI":457},{"title":495},{"VI":496},"Qubo Zhu",{"url":444,"publisher":498,"properties":525},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":499,"slug":10,"properties":500,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":503,"manageAffiliations":504,"indexDatabases":505,"url":18,"thumbnailPath":18,"statistic":520,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":501,"title":502},{"VOID":13},{"EN":15},[],[],[506,513],{"id":70,"indexDatabase":507,"url":85,"indexYears":18,"academicFieldIds":512,"indexDatabaseRanking":18},{"id":72,"createTime":73,"updateTime":74,"relativeEntities":508,"label":509,"description":510,"key":81,"publicationTags":511,"standard":18},[],{"EN":77,"VI":77},{"VI":79,"EN":80},[83,84],[87],{"id":89,"indexDatabase":514,"url":102,"indexYears":103,"academicFieldIds":519,"indexDatabaseRanking":108},{"id":91,"createTime":92,"updateTime":93,"relativeEntities":515,"label":516,"description":517,"key":99,"publicationTags":518,"standard":18},[],{"EN":96,"VI":96},{"EN":96,"VI":98},[101],[105,106,107],{"impactFactor":19,"impactFactorByYear":521,"i10Index":116,"i10IndexLast5Year":19,"totalPublication":117,"totalPublicationByYear":522,"totalCitation":132,"totalCitationByYear":523,"totalCitationPerPublication":145,"totalCitationPerPublicationByYear":524,"hindexLast5Year":116,"hindex":116},{"2012":111,"2013":112,"2014":113,"2015":114,"2019":115},{"2002":119,"2003":120,"2004":121,"2005":121,"2006":122,"2007":119,"2008":119,"2009":123,"2010":124,"2011":124,"2012":125,"2013":126,"2014":127,"2015":123,"2016":124,"2017":128,"2018":129,"2019":129,"2020":127,"2021":125,"2022":130,"2023":131,"2024":56},{"2003":134,"2004":135,"2005":136,"2006":137,"2007":138,"2008":139,"2009":140,"2011":141,"2012":142,"2013":143,"2018":144},{"2003":147,"2004":148,"2005":149,"2006":150,"2007":151,"2008":152,"2009":153,"2011":154,"2012":151,"2013":155,"2018":156},{"volume":526,"pages":528},{"VOID":527},"29",{"VOID":529},"317-324","2014-01-01",2014,{"id":533,"createTime":534,"updateTime":535,"relativeEntities":536,"slug":537,"properties":538,"entityType":174,"verifyStatus":175,"verifyTime":535,"verifyNote":177,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":545,"fullTextUrl":18,"authors":546,"publicationType":253,"publisherRelationship":646,"citationCount":18,"citationInfo":18,"publishDate":530,"publishYear":531,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":289},"443c5584-02ee-4e84-abaa-c53a3e12b551","2023-12-21T23:26:58.606+00:00","2025-02-10T23:51:45.563+00:00",[],"Differences-in-the-Glucuronidation-of-Resveratrol-and-Pterostilbene-Altered-Enzyme-Specificity-and-Potential-Gender-Differences",{"references":539,"title":541,"doi":543},{"VOID":540},"Park, 2008, Protective effects of resveratrol on UVB-irradiated HaCaT cells through attenuation of the caspase pathway, Oncol. Rep., 19, 413\nYu, 2012, Cellular and molecular effects of resveratrol in health and disease, J. Cell. Biochem., 113, 752, 10.1002\u002Fjcb.23431\nJang, 1997, Cancer chemopreventive activity of resveratrol, a natural product derived from grapes, Science, 275, 218, 10.1126\u002Fscience.275.5297.218\nNdiaye, 2011, The grape antioxidant resveratrol for skin disorders: Promise, prospects, and challenges, Arch. Biochem. Biophys., 508, 164, 10.1016\u002Fj.abb.2010.12.030\nRoupe, 2006, Pharmacometrics of stilbenes: seguing towards the clinic, Curr. Clin. Pharmacol., 1, 81, 10.2174\u002F157488406775268246\nCottart, 2010, Resveratrol bioavailability and toxicity in humans, Mol. Nutr. Food Res., 54, 7, 10.1002\u002Fmnfr.200900437\nBrill, 2006, Glucuronidation of trans-resveratrol by human liver and intestinal microsomes and UGT isoforms, J. Pharm. Pharmacol., 58, 469, 10.1211\u002Fjpp.58.4.0006\nAumont, 2001, Regioselective and stereospecific glucuronidation of trans- and cis-resveratrol in human, Arch. Biochem. Biophys., 393, 281, 10.1006\u002Fabbi.2001.2496\nTukey, 2000, Human UDP-glucuronosyltransferases: metabolism, expression, and disease, Annu. Rev. Pharmacol. Toxicol., 40, 581, 10.1146\u002Fannurev.pharmtox.40.1.581\nNagar, 2006, Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer, Oncogene, 25, 1659, 10.1038\u002Fsj.onc.1209375\nDellinger, 2007, Glucuronidation of PhIP and N-OH-PhIP by UDP-glucuronosyltransferase 1A10, Carcinogenesis, 28, 2412, 10.1093\u002Fcarcin\u002Fbgm164\nBasu, 2005, Phosphorylation of a UDP-glucuronosyltransferase regulates substrate specificity, Proc. Natl. Acad. Sci. USA, 102, 6285, 10.1073\u002Fpnas.0407872102\nChouinard, 2008, Inactivation by UDP-glucuronosyltransferase enzymes: the end of androgen signaling, J. Steroid Biochem. Mol. Biol., 109, 247, 10.1016\u002Fj.jsbmb.2008.03.016\nStarlard-Davenport, 2008, Identification of UDP-glucuronosyltransferase 1A10 in non-malignant and malignant human breast tissues, Steroids, 73, 611, 10.1016\u002Fj.steroids.2008.01.019\nMaier-Salamon, 2011, Hepatic glucuronidation of resveratrol: interspecies comparison of enzyme kinetic profiles in human, mouse, rat, and dog, Drug Metab. Pharmacokinet., 26, 364, 10.2133\u002Fdmpk.DMPK-11-RG-006\nSmoliga, 2011, Resveratrol and health—a comprehensive review of human clinical trials, Mol. Nutr. Food Res., 55, 1129, 10.1002\u002Fmnfr.201100143\nGokce, 2012, Resveratrol-loaded solid lipid nanoparticles versus nano-structured lipid carriers: evaluation of antioxidant potential for dermal applications, Int. J. Nanomedicine, 7, 1841, 10.2147\u002FIJN.S29710\nMcCormack, 2012, Pterostilbene and cancer: current review, J. Surg. Res., 173, e53, 10.1016\u002Fj.jss.2011.09.054\nHougee, 2005, Selective COX-2 inhibition by a Pterocarpus marsupium extract characterized by pterostilbene, and its activity in healthy human volunteers, Planta Med., 71, 387, 10.1055\u002Fs-2005-864130\nTsai, 2012, Pterostilbene, a natural analogue of resveratrol, potently inhibits 7,12-dimethylbenz[a]anthracene (DMBA)\u002F12-O-tetradecanoylphorbol-13-acetate (TPA)-induced mouse skin carcinogenesis, Food Funct, 3, 1185, 10.1039\u002Fc2fo30105a\nChiou, 2011, Pterostilbene is more potent than resveratrol in preventing azoxymethane (AOM)-induced colon tumorigenesis via activation of the NF-E2-related factor 2 (Nrf2)-mediated antioxidant signaling pathway, J. Agric. Food Chem., 59, 2725, 10.1021\u002Fjf2000103\nPan, 2009, Pterostilbene inhibited tumor invasion via suppressing multiple signal transduction pathways in human hepatocellular carcinoma cells, Carcinogenesis, 30, 1234, 10.1093\u002Fcarcin\u002Fbgp121\nKapetanovic, 2011, Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats, Cancer Chemother. Pharmacol., 68, 593, 10.1007\u002Fs00280-010-1525-4\nOlson, 2009, Functional characterization of low-prevalence missense polymorphisms in the UDP-glucuronosyltransferase 1A9 gene, Drug Metab. Dispos., 37, 1999, 10.1124\u002Fdmd.108.024596\nDellinger, 2006, Importance of UDP-glucuronosyltransferase 1A10 (UGT1A10) in the detoxification of polycyclic aromatic hydrocarbons: decreased glucuronidative activity of the UGT1A10139Lys isoform, Drug Metab. Dispos., 34, 943, 10.1124\u002Fdmd.105.009100\nSun, 2007, Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases, Drug Metab. Dispos., 35, 2006, 10.1124\u002Fdmd.107.017145\nShao, 2010, Structural identification of mouse urinary metabolites of pterostilbene using liquid chromatography\u002Ftandem mass spectrometry, Rapid Commun. Mass Spectrom., 24, 1770, 10.1002\u002Frcm.4579\nMiley, 2007, Crystal structure of the cofactor-binding domain of the human phase II drug-metabolism enzyme UDP-glucuronosyltransferase 2B7, J. Mol. Biol., 369, 498, 10.1016\u002Fj.jmb.2007.03.066\nDong, 2012, Understanding substrate selectivity of human UDP-glucuronosyltransferases through QSAR modeling and analysis of homologous enzymes, Xenobiotica, 42, 808820, 10.3109\u002F00498254.2012.663515\nMiksits, 2005, Sulfation of resveratrol in human liver: evidence of a major role for the sulfotransferases SULT1A1 and SULT1E1, Xenobiotica, 35, 1101, 10.1080\u002F00498250500354253\nOhno, 2009, Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction, Drug Metab. Dispos., 37, 32, 10.1124\u002Fdmd.108.023598\nNavarro, 2011, Determinants of aspirin metabolism in healthy men and women: effects of dietary inducers of UDP-glucuronosyltransferases, J. Nutrigenet. Nutrigenomics, 4, 110, 10.1159\u002F000327782\nLiu, 2010, Species and gender differences affect the metabolism of emodin via glucuronidation, AAPS J., 12, 424, 10.1208\u002Fs12248-010-9200-6\nChen, 2009, Up-regulation of UDP-glucuronosyltransferase (UGT) 1A4 by 17beta-estradiol: a potential mechanism of increased lamotrigine elimination in pregnancy, Drug Metab. Dispos., 37, 1841, 10.1124\u002Fdmd.109.026609\nJeong, 2008, Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination, Xenobiotica, 38, 62, 10.1080\u002F00498250701744633\nStarlard-Davenport, 2008, Novel identification of UDP-glucuronosyltransferase 1A10 as an estrogen-regulated target gene, Steroids, 73, 139, 10.1016\u002Fj.steroids.2007.09.007\nHarrington, 2006, Estrogen regulation of the glucuronidation enzyme UGT2B15 in estrogen receptor-positive breast cancer cells, Endocrinology, 147, 3843, 10.1210\u002Fen.2006-0358",{"EN":542},"Differences in the Glucuronidation of Resveratrol and Pterostilbene: Altered Enzyme Specificity and Potential Gender Differences",{"VOID":544},"10.2133\u002Fdmpk.dmpk-13-rg-012","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS1347436715303062",[547,596,615],{"id":548,"sortIndex":56,"researcher":18,"roles":549,"affiliations":550,"properties":593},"7c1ad9d0-ad95-450c-8d1a-abc418eb3c8e",[183],[551,561,573,585],{"id":552,"sortIndex":373,"affiliation":553,"properties":560},"0bb90684-d271-48ab-ae82-e160756896da",{"id":554,"createTime":555,"updateTime":555,"relativeEntities":556,"slug":18,"properties":557,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"5fe9aa9d-3015-4297-bfa8-7cf52b427b6a","2023-12-31T20:05:14.559+00:00",[],{"title":558},{"VI":559},"Department of Public Health, University of California Irvine, Irvine, CA, USA",{},{"id":562,"sortIndex":56,"affiliation":563,"properties":572},"f9a4e91a-e216-4323-a606-565c8ae9ca6a",{"id":564,"createTime":565,"updateTime":566,"relativeEntities":567,"slug":568,"properties":569,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"6ccb39be-f4fa-44c7-8978-729732f91bee","2024-01-11T09:20:21.024+00:00","2024-09-23T10:05:31.590+00:00",[],"Department-of-Biological-Chemistry-University-of-California-Irvine-Irvine-CA-USA",{"title":570},{"VI":571},"Department of Biological Chemistry, University of California Irvine, Irvine, CA, USA",{},{"id":574,"sortIndex":144,"affiliation":575,"properties":584},"ba8361ac-d0c6-4c0e-a609-02ad49949d04",{"id":576,"createTime":577,"updateTime":578,"relativeEntities":579,"slug":580,"properties":581,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"0cd52032-91f5-47bc-ac23-fa93612c43f2","2023-12-23T13:50:53.907+00:00","2024-09-12T07:08:21.452+00:00",[],"Department-of-Medicine-University-of-California-Irvine-Irvine-CA-USA",{"title":582},{"VI":583},"Department of Medicine, University of California, Irvine, Irvine, CA, USA",{},{"id":18,"sortIndex":19,"affiliation":586,"properties":18},{"id":587,"createTime":588,"updateTime":588,"relativeEntities":589,"slug":18,"properties":590,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"15d8502b-c0eb-45f3-9eaf-17c27c70e4d9","2023-12-21T23:26:58.690+00:00",[],{"title":591},{"VI":592},"Chao Family Comprehensive Cancer Center, Department of Medicine, University of California Irvine, Irvine, CA, USA",{"title":594},{"VI":595},"Frank L. Meyskens",{"id":597,"sortIndex":144,"researcher":18,"roles":598,"affiliations":599,"properties":612},"3f569c6c-e648-4495-b6ca-be9b16cc0df1",[183],[600,605],{"id":18,"sortIndex":19,"affiliation":601,"properties":18},{"id":587,"createTime":588,"updateTime":588,"relativeEntities":602,"slug":18,"properties":603,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":604},{"VI":592},{"id":606,"sortIndex":144,"affiliation":607,"properties":611},"0f491ae2-5047-430a-b521-04eb304021c0",{"id":576,"createTime":577,"updateTime":578,"relativeEntities":608,"slug":580,"properties":609,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":610},{"VI":583},{},{"title":613},{"VI":614},"Angela M. Gomez Garcia",{"id":616,"sortIndex":19,"researcher":18,"roles":617,"affiliations":618,"properties":643},"b2b4bf62-b226-46d3-b0f5-7561ec665de3",[183],[619,624,634],{"id":18,"sortIndex":19,"affiliation":620,"properties":18},{"id":587,"createTime":588,"updateTime":588,"relativeEntities":621,"slug":18,"properties":622,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":623},{"VI":592},{"id":625,"sortIndex":56,"affiliation":626,"properties":633},"9a61ecbd-79d8-4f0e-ae73-f11e08f66e68",{"id":627,"createTime":628,"updateTime":628,"relativeEntities":629,"slug":18,"properties":630,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"8affe382-e2db-4f98-bc83-6e79081590da","2023-12-05T23:03:13.933+00:00",[],{"title":631},{"VI":632},"Department of Epidemiology, University of California, Irvine, Irvine, CA, USA",{},{"id":635,"sortIndex":144,"affiliation":636,"properties":640},"58ed3840-66ab-409e-b24a-d77c7a9f8219",{"id":576,"createTime":577,"updateTime":578,"relativeEntities":637,"slug":580,"properties":638,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":639},{"VI":583},{"title":641},{"VI":642},"Department of Medicine, University of California Irvine, Irvine, CA, USA",{"title":644},{"VI":645},"Ryan W. Dellinger",{"url":545,"publisher":647,"properties":674},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":648,"slug":10,"properties":649,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":652,"manageAffiliations":653,"indexDatabases":654,"url":18,"thumbnailPath":18,"statistic":669,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":650,"title":651},{"VOID":13},{"EN":15},[],[],[655,662],{"id":70,"indexDatabase":656,"url":85,"indexYears":18,"academicFieldIds":661,"indexDatabaseRanking":18},{"id":72,"createTime":73,"updateTime":74,"relativeEntities":657,"label":658,"description":659,"key":81,"publicationTags":660,"standard":18},[],{"EN":77,"VI":77},{"VI":79,"EN":80},[83,84],[87],{"id":89,"indexDatabase":663,"url":102,"indexYears":103,"academicFieldIds":668,"indexDatabaseRanking":108},{"id":91,"createTime":92,"updateTime":93,"relativeEntities":664,"label":665,"description":666,"key":99,"publicationTags":667,"standard":18},[],{"EN":96,"VI":96},{"EN":96,"VI":98},[101],[105,106,107],{"impactFactor":19,"impactFactorByYear":670,"i10Index":116,"i10IndexLast5Year":19,"totalPublication":117,"totalPublicationByYear":671,"totalCitation":132,"totalCitationByYear":672,"totalCitationPerPublication":145,"totalCitationPerPublicationByYear":673,"hindexLast5Year":116,"hindex":116},{"2012":111,"2013":112,"2014":113,"2015":114,"2019":115},{"2002":119,"2003":120,"2004":121,"2005":121,"2006":122,"2007":119,"2008":119,"2009":123,"2010":124,"2011":124,"2012":125,"2013":126,"2014":127,"2015":123,"2016":124,"2017":128,"2018":129,"2019":129,"2020":127,"2021":125,"2022":130,"2023":131,"2024":56},{"2003":134,"2004":135,"2005":136,"2006":137,"2007":138,"2008":139,"2009":140,"2011":141,"2012":142,"2013":143,"2018":144},{"2003":147,"2004":148,"2005":149,"2006":150,"2007":151,"2008":152,"2009":153,"2011":154,"2012":151,"2013":155,"2018":156},{"volume":675,"pages":676},{"VOID":527},{"VOID":677},"112-119",{"id":679,"createTime":680,"updateTime":681,"relativeEntities":682,"slug":683,"properties":684,"entityType":174,"verifyStatus":175,"verifyTime":681,"verifyNote":177,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":56,"primaryUrl":691,"fullTextUrl":18,"authors":692,"publicationType":253,"publisherRelationship":855,"citationCount":18,"citationInfo":18,"publishDate":888,"publishYear":889,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":289},"daa46ee0-6dba-4551-af53-a854703b867b","2023-11-25T20:33:46.870+00:00","2025-02-16T23:46:20.497+00:00",[],"Functional-characterization-of-10-CYP4A11-allelic-variants-to-evaluate-the-effect-of-genotype-on-arachidonic-acid-%CF%89-hydroxylation",{"references":685,"title":687,"doi":689},{"VOID":686},"Stokes, 1989, Blood pressure as a risk factor for cardiovascular disease. The Framingham Study–30 years of follow-up, Hypertension, 13, I13, 10.1161\u002F01.HYP.13.5_Suppl.I13\nBarri, 2006, Hypertension and kidney disease: a deadly connection, Curr Cardiol Rep, 8, 411, 10.1007\u002Fs11886-006-0098-7\nHalushka, 1999, Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis, Nat Genet, 22, 239, 10.1038\u002F10297\nZou, 1996, 20-HETE is an endogenous inhibitor of the large-conductance Ca(2+)-activated K+ channel in renal arterioles, Am J Physiol, 270, R228\nMa, 1993, 20-Hydroxyeicosatetraenoic acid is an endogenous vasoconstrictor of canine renal arcuate arteries, Circ Res, 72, 126, 10.1161\u002F01.RES.72.1.126\nSchwartzman, 1985, Renal cytochrome P450-related arachidonate metabolite inhibits (Na+ + K+)ATPase, Nature, 314, 620, 10.1038\u002F314620a0\nNowicki, 1997, 20-Hydroxyeicosa-tetraenoic acid (20 HETE) activates protein kinase C. Role in regulation of rat renal Na+,K+-ATPase, J Clin Invest, 99, 1224, 10.1172\u002FJCI119279\nSugimoto, 2008, A polymorphism regulates CYP4A11 transcriptional activity and is associated with hypertension in a Japanese population, Hypertension, 52, 1142, 10.1161\u002FHYPERTENSIONAHA.108.114082\nFu, 2013, A novel polymorphism of the CYP4A11 gene is associated with coronary artery disease, Clin Appl Thromb Hemost, 19, 60, 10.1177\u002F1076029611436197\nFu, 2013, Haplotype study of the CYP4A11 gene and coronary artery disease in Han and Uygur populations in China, Gene, 512, 510, 10.1016\u002Fj.gene.2012.10.007\nFu, 2012, Haplotype-based case-control study of CYP4A11 gene and myocardial infarction, Hereditas, 149, 91, 10.1111\u002Fj.1601-5223.2012.02247.x\nGainer, 2005, Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension, Circulation, 111, 63, 10.1161\u002F01.CIR.0000151309.82473.59\nMayer, 2005, Association of the T8590C polymorphism of CYP4A11 with hypertension in the MONICA Augsburg echocardiographic substudy, Hypertension, 46, 766, 10.1161\u002F01.HYP.0000182658.04299.15\nFu, 2008, A haplotype of the CYP4A11 gene associated with essential hypertension in Japanese men, J Hypertens, 26, 453, 10.1097\u002FHJH.0b013e3282f2f10c\nWilliams, 2011, CYP4A11 T8590C polymorphism, salt-sensitive hypertension, and renal blood flow, J Hypertens, 29, 1913, 10.1097\u002FHJH.0b013e32834aa786\nPowell, 1998, Metabolism of arachidonic acid to 20-hydroxy-5,8,11, 14-eicosatetraenoic acid by P450 enzymes in human liver: involvement of CYP4F2 and CYP4A11, J Pharmacol Exp Ther, 285, 1327\nChang, 1999, Homology modeling and substrate binding study of human CYP4A11 enzyme, Proteins, 34, 403, 10.1002\u002F(SICI)1097-0134(19990215)34:3\u003C403::AID-PROT12>3.0.CO;2-D\nLino Cardenas, 2011, Genetic polymorphism of CYP4A11 and CYP4A22 genes and in silico insights from comparative 3D modelling in a French population, Gene, 487, 10, 10.1016\u002Fj.gene.2011.07.015\n1993\nGainer, 2008, Association of a CYP4A11 variant and blood pressure in black men, J Am Soc Nephrol, 19, 1606, 10.1681\u002FASN.2008010063",{"EN":688},"Functional characterization of 10 CYP4A11 allelic variants to evaluate the effect of genotype on arachidonic acid ω-hydroxylation",{"VOID":690},"10.1016\u002Fj.dmpk.2014.09.001","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS1347436714000020",[693,710,726,744,756,768,780,793,805,818,830,842],{"id":694,"sortIndex":695,"researcher":18,"roles":696,"affiliations":697,"properties":707},"c44033a0-6b46-4292-b33e-dbd20cf3837d",7,[183],[698],{"id":18,"sortIndex":19,"affiliation":699,"properties":18},{"id":700,"createTime":701,"updateTime":701,"relativeEntities":702,"slug":703,"properties":704,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"7408a6a1-b0cf-4d1e-99b8-0cf46a498865","2023-11-25T20:33:46.920+00:00",[],"Department-of-Integrative-Genomics-Tohoku-Medical-Megabank-Tohoku-University-Sendai-Japan",{"title":705},{"VI":706},"Department of Integrative Genomics, Tohoku Medical Megabank, Tohoku University, Sendai, Japan",{"title":708},{"VI":709},"Daisuke Saigusa",{"id":711,"sortIndex":345,"researcher":18,"roles":712,"affiliations":713,"properties":723},"0edf3037-b5b3-4a7c-b642-07294a7ccaaa",[183],[714],{"id":18,"sortIndex":19,"affiliation":715,"properties":18},{"id":716,"createTime":717,"updateTime":717,"relativeEntities":718,"slug":719,"properties":720,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"ef54e5c7-2706-447c-8368-dc5e1be3320f","2023-11-25T20:33:46.892+00:00",[],"Laboratory-of-Pharmacotherapy-of-Life-Style-Related-Disease-Graduate-School-of-Pharmaceutical-Sciences-Tohoku-University-Sendai-Japan",{"title":721},{"VI":722},"Laboratory of Pharmacotherapy of Life-Style Related Disease, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan",{"title":724},{"VI":725},"Miyabi Ito",{"id":727,"sortIndex":728,"researcher":18,"roles":729,"affiliations":730,"properties":741},"c342fe7d-b33c-44c9-85de-5166be8eb474",8,[183],[731],{"id":18,"sortIndex":19,"affiliation":732,"properties":18},{"id":733,"createTime":734,"updateTime":735,"relativeEntities":736,"slug":737,"properties":738,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"11e8f586-a130-4ff9-8a14-20c7a1a93731","2023-11-25T20:33:46.925+00:00","2024-10-17T03:17:36.371+00:00",[],"Laboratory-of-Oncology-Pharmacy-Practice-and-Sciences-Graduate-School-of-Pharmaceutical-Sciences-Tohoku-University-Sendai-Japan",{"title":739},{"VI":740},"Laboratory of Oncology, Pharmacy Practice and Sciences, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan",{"title":742},{"VI":743},"Naoto Suzuki",{"id":745,"sortIndex":373,"researcher":18,"roles":746,"affiliations":747,"properties":753},"4474b976-8697-44d4-9781-3772ed7601b9",[183],[748],{"id":18,"sortIndex":19,"affiliation":749,"properties":18},{"id":716,"createTime":717,"updateTime":717,"relativeEntities":750,"slug":719,"properties":751,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":752},{"VI":722},{"title":754},{"VI":755},"Chiharu Tsukada",{"id":757,"sortIndex":307,"researcher":18,"roles":758,"affiliations":759,"properties":765},"4d67f6b1-fc41-4efc-be8d-7f8c19324435",[183],[760],{"id":18,"sortIndex":19,"affiliation":761,"properties":18},{"id":716,"createTime":717,"updateTime":717,"relativeEntities":762,"slug":719,"properties":763,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":764},{"VI":722},{"title":766},{"VI":767},"Yuki Katono",{"id":769,"sortIndex":144,"researcher":18,"roles":770,"affiliations":771,"properties":777},"c5285029-9703-4d5f-a2e2-4b8b1310314a",[183],[772],{"id":18,"sortIndex":19,"affiliation":773,"properties":18},{"id":716,"createTime":717,"updateTime":717,"relativeEntities":774,"slug":719,"properties":775,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":776},{"VI":722},{"title":778},{"VI":779},"Masashi Honda",{"id":781,"sortIndex":782,"researcher":18,"roles":783,"affiliations":784,"properties":790},"0d62793d-e24e-4e0e-bef2-e6341b46e29e",10,[183],[785],{"id":18,"sortIndex":19,"affiliation":786,"properties":18},{"id":716,"createTime":717,"updateTime":717,"relativeEntities":787,"slug":719,"properties":788,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":789},{"VI":722},{"title":791},{"VI":792},"Noriyasu Hirasawa",{"id":794,"sortIndex":56,"researcher":18,"roles":795,"affiliations":796,"properties":802},"823646d4-a975-480c-a5f7-a00070b5d7b8",[183],[797],{"id":18,"sortIndex":19,"affiliation":798,"properties":18},{"id":716,"createTime":717,"updateTime":717,"relativeEntities":799,"slug":719,"properties":800,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":801},{"VI":722},{"title":803},{"VI":804},"Masamitsu Takahashi",{"id":806,"sortIndex":807,"researcher":18,"roles":808,"affiliations":809,"properties":815},"4c583970-99da-4a2b-bd7d-4396bb174acd",6,[183],[810],{"id":18,"sortIndex":19,"affiliation":811,"properties":18},{"id":716,"createTime":717,"updateTime":717,"relativeEntities":812,"slug":719,"properties":813,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":814},{"VI":722},{"title":816},{"VI":817},"Hiroki Hosono",{"id":819,"sortIndex":19,"researcher":18,"roles":820,"affiliations":821,"properties":827},"ca8b65e2-656c-48af-9711-5f0e1288e130",[183],[822],{"id":18,"sortIndex":19,"affiliation":823,"properties":18},{"id":716,"createTime":717,"updateTime":717,"relativeEntities":824,"slug":719,"properties":825,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":826},{"VI":722},{"title":828},{"VI":829},"Takahiro Saito",{"id":831,"sortIndex":832,"researcher":18,"roles":833,"affiliations":834,"properties":840},"a542a3db-e67a-4dff-8db0-eccaf30cd216",11,[183],[835],{"id":18,"sortIndex":19,"affiliation":836,"properties":18},{"id":716,"createTime":717,"updateTime":717,"relativeEntities":837,"slug":719,"properties":838,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":839},{"VI":722},{"title":841},{"VI":370},{"id":843,"sortIndex":844,"researcher":18,"roles":845,"affiliations":846,"properties":852},"1bbdb899-b807-49f8-80d3-762c97216a0b",9,[183],[847],{"id":18,"sortIndex":19,"affiliation":848,"properties":18},{"id":733,"createTime":734,"updateTime":735,"relativeEntities":849,"slug":737,"properties":850,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":851},{"VI":740},{"title":853},{"VI":854},"Yoshihisa Tomioka",{"url":691,"publisher":856,"properties":883},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":857,"slug":10,"properties":858,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":861,"manageAffiliations":862,"indexDatabases":863,"url":18,"thumbnailPath":18,"statistic":878,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":859,"title":860},{"VOID":13},{"EN":15},[],[],[864,871],{"id":70,"indexDatabase":865,"url":85,"indexYears":18,"academicFieldIds":870,"indexDatabaseRanking":18},{"id":72,"createTime":73,"updateTime":74,"relativeEntities":866,"label":867,"description":868,"key":81,"publicationTags":869,"standard":18},[],{"EN":77,"VI":77},{"VI":79,"EN":80},[83,84],[87],{"id":89,"indexDatabase":872,"url":102,"indexYears":103,"academicFieldIds":877,"indexDatabaseRanking":108},{"id":91,"createTime":92,"updateTime":93,"relativeEntities":873,"label":874,"description":875,"key":99,"publicationTags":876,"standard":18},[],{"EN":96,"VI":96},{"EN":96,"VI":98},[101],[105,106,107],{"impactFactor":19,"impactFactorByYear":879,"i10Index":116,"i10IndexLast5Year":19,"totalPublication":117,"totalPublicationByYear":880,"totalCitation":132,"totalCitationByYear":881,"totalCitationPerPublication":145,"totalCitationPerPublicationByYear":882,"hindexLast5Year":116,"hindex":116},{"2012":111,"2013":112,"2014":113,"2015":114,"2019":115},{"2002":119,"2003":120,"2004":121,"2005":121,"2006":122,"2007":119,"2008":119,"2009":123,"2010":124,"2011":124,"2012":125,"2013":126,"2014":127,"2015":123,"2016":124,"2017":128,"2018":129,"2019":129,"2020":127,"2021":125,"2022":130,"2023":131,"2024":56},{"2003":134,"2004":135,"2005":136,"2006":137,"2007":138,"2008":139,"2009":140,"2011":141,"2012":142,"2013":143,"2018":144},{"2003":147,"2004":148,"2005":149,"2006":150,"2007":151,"2008":152,"2009":153,"2011":154,"2012":151,"2013":155,"2018":156},{"volume":884,"pages":886},{"VOID":885},"30",{"VOID":887},"119-122","2015-02-01",2015,{"id":891,"createTime":892,"updateTime":893,"relativeEntities":894,"slug":895,"properties":896,"entityType":174,"verifyStatus":175,"verifyTime":893,"verifyNote":177,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":903,"fullTextUrl":18,"authors":904,"publicationType":253,"publisherRelationship":971,"citationCount":18,"citationInfo":18,"publishDate":1004,"publishYear":1005,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":289},"7d949dde-3ca7-4627-9930-9b5590c55825","2024-01-09T06:31:14.949+00:00","2025-01-10T23:45:53.117+00:00",[],"Population-Pharmacokinetics-of-an-Angiotensin-II-Receptor-Antagonist-Telmisartan-in-Healthy-Volunteers-and-Hypertensive-Patients",{"references":897,"title":899,"doi":901},{"VOID":898},"Wienen, 1993, Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277, Br. J. Pharmacol., 110, 245, 10.1111\u002Fj.1476-5381.1993.tb13800.x\nWienen, 2000, A review on telmisartan: a novel, long- acting angiotensin Il-receptor antagonist, Cardiovasc Drug Rev., 18, 127, 10.1111\u002Fj.1527-3466.2000.tb00039.x\nNeutel, 1998, Dose response and antihypertensive efficacy of the AT1 receptor antagonist telmisartan in patients with mild to moderate hypertension, Adv. Ther., 15, 206\nSmith, 2000, Dose response and safety of telmisartan in patients with mild to moderate hypertension, J. Clin. Pharmacol., 40, 1380, 10.1177\u002F009127000004001210\nStangier, 2000, Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients, J. Int. Med. Res., 28, 149, 10.1177\u002F147323000002800401\nStangier, 2000, Absorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteers, J. Clin. Pharmacol., 40, 1312, 10.1177\u002F009127000004001202\nStangier, 2000, Pharmacokinetics and safety of intravenous and oral telmisartan 20mg and 120mg in subjects with hepatic impairment compared with healthy volunteers, J. Clin. Pharmacol., 40, 1355, 10.1177\u002F009127000004001207\nWilliams, 2000, The role of population pharmacokinetics in drug development in light of the Food and Drug Administration’s ‘Guidance for industry: population pharmacokinetics’, Clin. Pharmacokinet., 39, 385, 10.2165\u002F00003088-200039060-00001\nFDA, 1999\nOgihara, 2002, Pharmacokinetic evaluation of an angiotensin II AT1 receptor antagonist, BIBR277 (Telmisartan) in hypertensive patients, Jpn. Pharmacol. Ther. (in Japanese), 30, S271\nOgihara, 2002, Pharmacokinetics of BIBR277 (Telmisartan) in hypertensive patients with renal insufficiency, Jpn. Pharmacol. Ther. (in Japanese), 30, S183\nOgihara, 2002, Pharmacokinetics of BIBR277 (Telmisartan) in patients with essential hypertension, Jpn. Pharmacol. Ther. (in Japanese), 30, S235\nIrie, 2002, Influence of food on the bioavailability of single oral dose of BIBR277 (Telmisartan), Jpn. Pharmacol. Ther. (in Japanese), 30, S201\nBoeckmann, 1998\nEtte, 1997, Stability and performance of a population pharmacokinetic model, J. Clin. Pharmacol., 37, 486, 10.1002\u002Fj.1552-4604.1997.tb04326.x\nIsraili, 2000, Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension, J. Hum. Hypertens., 14, S73, 10.1038\u002Fsj.jhh.1000991\nSharpe, 2001, Telmisartan: a review of its use in hypertension, Drugs, 61, 1501, 10.2165\u002F00003495-200161100-00009\nSchmid, 1996, In vivo and in vitro biotransformation of telmisartan, human hepatocyte cultures as an aid in human metabolic studies, Exp. Toxicol. Pathol., 48, 387\nEbner, 1999, In vitro glucuronidation of telmisartan, a novel angiotensin II receptor antagonist, J. Hum. Hypertens., 13, S12\nMackenzie, 2000, Polymorphisms in UDP glucuronosyltransferase genes: functional consequences and clinical relevance, Clin. Chem. Lab. Med., 38, 889, 10.1515\u002FCCLM.2000.129",{"EN":900},"Population Pharmacokinetics of an Angiotensin II Receptor Antagonist, Telmisartan, in Healthy Volunteers and Hypertensive Patients",{"VOID":902},"10.2133\u002Fdmpk.18.203","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS1347436715308831",[905,920,932,944,956],{"id":906,"sortIndex":144,"researcher":18,"roles":907,"affiliations":908,"properties":917},"0eb30692-dfaf-43b9-9d1e-0b75a171fd4a",[183],[909],{"id":18,"sortIndex":19,"affiliation":910,"properties":18},{"id":911,"createTime":912,"updateTime":912,"relativeEntities":913,"slug":18,"properties":914,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"7aa7e1db-9946-4945-9e28-de297a2cd337","2024-01-09T06:31:15.040+00:00",[],{"title":915},{"VI":916},"Department of Drug Metabolism and Pharmacokinetics, Kawanishi Pharma Research Institute, Nippon Boehringer Ingelheim Co., Ltd., Kawanishi, Japan",{"title":918},{"VI":919},"Akiko Sarashina",{"id":921,"sortIndex":56,"researcher":18,"roles":922,"affiliations":923,"properties":929},"39759ecd-6ebf-4bb1-8d9a-dbebb36873ef",[183],[924],{"id":18,"sortIndex":19,"affiliation":925,"properties":18},{"id":911,"createTime":912,"updateTime":912,"relativeEntities":926,"slug":18,"properties":927,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":928},{"VI":916},{"title":930},{"VI":931},"Norio Yamamura",{"id":933,"sortIndex":373,"researcher":18,"roles":934,"affiliations":935,"properties":941},"0e461ad8-8e3f-413d-a1e6-11b99f2d9075",[183],[936],{"id":18,"sortIndex":19,"affiliation":937,"properties":18},{"id":911,"createTime":912,"updateTime":912,"relativeEntities":938,"slug":18,"properties":939,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":940},{"VI":916},{"title":942},{"VI":943},"Takashi Igarashi",{"id":945,"sortIndex":19,"researcher":18,"roles":946,"affiliations":947,"properties":953},"d96b61bf-9903-4a55-bc8f-b8d3f334fb3d",[183],[948],{"id":18,"sortIndex":19,"affiliation":949,"properties":18},{"id":911,"createTime":912,"updateTime":912,"relativeEntities":950,"slug":18,"properties":951,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":952},{"VI":916},{"title":954},{"VI":955},"Shinji Tatami",{"id":957,"sortIndex":345,"researcher":18,"roles":958,"affiliations":959,"properties":968},"e7533cf3-4863-48b3-b2f5-b272dc682703",[183],[960],{"id":18,"sortIndex":19,"affiliation":961,"properties":18},{"id":962,"createTime":963,"updateTime":963,"relativeEntities":964,"slug":18,"properties":965,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"8e088411-7369-4b63-9e8d-31bb3947680f","2024-01-09T06:31:15.099+00:00",[],{"title":966},{"VI":967},"Department of Hospital Pharmacy, School of Medicine, Keio University, Tokyo Japan",{"title":969},{"VI":970},"Yusuke Tanigawara",{"url":903,"publisher":972,"properties":999},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":973,"slug":10,"properties":974,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":977,"manageAffiliations":978,"indexDatabases":979,"url":18,"thumbnailPath":18,"statistic":994,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":975,"title":976},{"VOID":13},{"EN":15},[],[],[980,987],{"id":70,"indexDatabase":981,"url":85,"indexYears":18,"academicFieldIds":986,"indexDatabaseRanking":18},{"id":72,"createTime":73,"updateTime":74,"relativeEntities":982,"label":983,"description":984,"key":81,"publicationTags":985,"standard":18},[],{"EN":77,"VI":77},{"VI":79,"EN":80},[83,84],[87],{"id":89,"indexDatabase":988,"url":102,"indexYears":103,"academicFieldIds":993,"indexDatabaseRanking":108},{"id":91,"createTime":92,"updateTime":93,"relativeEntities":989,"label":990,"description":991,"key":99,"publicationTags":992,"standard":18},[],{"EN":96,"VI":96},{"EN":96,"VI":98},[101],[105,106,107],{"impactFactor":19,"impactFactorByYear":995,"i10Index":116,"i10IndexLast5Year":19,"totalPublication":117,"totalPublicationByYear":996,"totalCitation":132,"totalCitationByYear":997,"totalCitationPerPublication":145,"totalCitationPerPublicationByYear":998,"hindexLast5Year":116,"hindex":116},{"2012":111,"2013":112,"2014":113,"2015":114,"2019":115},{"2002":119,"2003":120,"2004":121,"2005":121,"2006":122,"2007":119,"2008":119,"2009":123,"2010":124,"2011":124,"2012":125,"2013":126,"2014":127,"2015":123,"2016":124,"2017":128,"2018":129,"2019":129,"2020":127,"2021":125,"2022":130,"2023":131,"2024":56},{"2003":134,"2004":135,"2005":136,"2006":137,"2007":138,"2008":139,"2009":140,"2011":141,"2012":142,"2013":143,"2018":144},{"2003":147,"2004":148,"2005":149,"2006":150,"2007":151,"2008":152,"2009":153,"2011":154,"2012":151,"2013":155,"2018":156},{"volume":1000,"pages":1002},{"VOID":1001},"18",{"VOID":1003},"203-211","2003-01-01",2003,{"id":1007,"createTime":1008,"updateTime":1009,"relativeEntities":1010,"slug":1011,"properties":1012,"entityType":174,"verifyStatus":175,"verifyTime":1019,"verifyNote":177,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":1020,"fullTextUrl":18,"authors":1021,"publicationType":253,"publisherRelationship":1068,"citationCount":807,"citationInfo":1100,"publishDate":1102,"publishYear":288,"citationAnalyzeStatus":17,"lastCitationAnalyze":1009,"indexDatabases":18,"openAccess":18,"references":1103,"isForceReanalyzing":289},"5663d150-2b83-4c8e-8073-864feb04e0fb","2023-12-02T21:01:00.244+00:00","2026-03-18T23:44:22.881+00:00",[],"Molecular-cloning-sequence-analysis-and-tissue-distribution-of-marmoset-monoamine-oxidases-A-and-B",{"title":1013,"doi":1015,"gsPaper":1017},{"EN":1014},"Molecular cloning, sequence analysis, and tissue distribution of marmoset monoamine oxidases A and B",{"VOID":1016},"10.1016\u002Fj.dmpk.2020.06.002",{"VOID":1018},"[\"18016554764390958741\"]","2024-05-03T17:39:33.462+00:00","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS134743672030375X",[1022,1039,1051],{"id":1023,"sortIndex":56,"researcher":18,"roles":1024,"affiliations":1025,"properties":1034},"014cdc46-fa1d-470f-b8aa-7e377fa3457a",[183],[1026],{"id":18,"sortIndex":19,"affiliation":1027,"properties":18},{"id":1028,"createTime":1029,"updateTime":1029,"relativeEntities":1030,"slug":18,"properties":1031,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"11d54702-3685-4114-b24c-e4e633a1dd00","2023-12-19T12:14:52.890+00:00",[],{"title":1032},{"VI":1033},"Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Machida, Japan",{"title":1035,"gsAuthor":1037},{"VI":1036},"Hiroshi Yamazaki",{"VOID":1038},"[\"1EuTAW8AAAAJ\"]",{"id":1040,"sortIndex":19,"researcher":18,"roles":1041,"affiliations":1042,"properties":1048},"b7d7d399-fdad-4c62-9153-d900f5ce7d05",[183],[1043],{"id":18,"sortIndex":19,"affiliation":1044,"properties":18},{"id":1028,"createTime":1029,"updateTime":1029,"relativeEntities":1045,"slug":18,"properties":1046,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1047},{"VI":1033},{"title":1049},{"VI":1050},"Shotaro Uehara",{"id":1052,"sortIndex":144,"researcher":18,"roles":1053,"affiliations":1054,"properties":1063},"fe54c6a6-f5ad-4db3-9294-a8a6ae797408",[183],[1055],{"id":18,"sortIndex":19,"affiliation":1056,"properties":18},{"id":1057,"createTime":1058,"updateTime":1058,"relativeEntities":1059,"slug":18,"properties":1060,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"67962f57-bacc-48b0-af96-a7e10d9f2293","2023-12-01T14:02:14.083+00:00",[],{"title":1061},{"VI":1062},"Joint Faculty of Veterinary Medicine, Kagoshima University, Kagoshima-city, Japan",{"title":1064,"gsAuthor":1066},{"VI":1065},"Yasuhiro Uno",{"VOID":1067},"[\"RbeWCBsAAAAJ\"]",{"url":1020,"publisher":1069,"properties":1096},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1070,"slug":10,"properties":1071,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":1074,"manageAffiliations":1075,"indexDatabases":1076,"url":18,"thumbnailPath":18,"statistic":1091,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":1072,"title":1073},{"VOID":13},{"EN":15},[],[],[1077,1084],{"id":70,"indexDatabase":1078,"url":85,"indexYears":18,"academicFieldIds":1083,"indexDatabaseRanking":18},{"id":72,"createTime":73,"updateTime":74,"relativeEntities":1079,"label":1080,"description":1081,"key":81,"publicationTags":1082,"standard":18},[],{"EN":77,"VI":77},{"VI":79,"EN":80},[83,84],[87],{"id":89,"indexDatabase":1085,"url":102,"indexYears":103,"academicFieldIds":1090,"indexDatabaseRanking":108},{"id":91,"createTime":92,"updateTime":93,"relativeEntities":1086,"label":1087,"description":1088,"key":99,"publicationTags":1089,"standard":18},[],{"EN":96,"VI":96},{"EN":96,"VI":98},[101],[105,106,107],{"impactFactor":19,"impactFactorByYear":1092,"i10Index":116,"i10IndexLast5Year":19,"totalPublication":117,"totalPublicationByYear":1093,"totalCitation":132,"totalCitationByYear":1094,"totalCitationPerPublication":145,"totalCitationPerPublicationByYear":1095,"hindexLast5Year":116,"hindex":116},{"2012":111,"2013":112,"2014":113,"2015":114,"2019":115},{"2002":119,"2003":120,"2004":121,"2005":121,"2006":122,"2007":119,"2008":119,"2009":123,"2010":124,"2011":124,"2012":125,"2013":126,"2014":127,"2015":123,"2016":124,"2017":128,"2018":129,"2019":129,"2020":127,"2021":125,"2022":130,"2023":131,"2024":56},{"2003":134,"2004":135,"2005":136,"2006":137,"2007":138,"2008":139,"2009":140,"2011":141,"2012":142,"2013":143,"2018":144},{"2003":147,"2004":148,"2005":149,"2006":150,"2007":151,"2008":152,"2009":153,"2011":154,"2012":151,"2013":155,"2018":156},{"volume":1097,"pages":1098},{"VOID":284},{"VOID":1099},"479-482",{"total":807,"publishYear":288,"statisticByYear":1101},{"2020":56,"2022":56,"2023":56},"2020-10-01",[1104,1113,1121,1127,1136,1144,1152,1160,1168,1174,1182,1191,1194,1198,1206,1212,1218,1227,1232,1235,1241,1250,1255,1261,1269,1278,1287,1291,1299,1302,1310,1318,1322],{"id":18,"text":1105,"url":1106,"identifiers":1107},"Shih, 2018, Monoamine oxidase isoenzymes: genes, functions and targets for behavior and cancer therapy, J Neural Transm, 125, 1553, 10.1007\u002Fs00702-018-1927-8","https:\u002F\u002Fdoi.org\u002F10.1007\u002Fs00702-018-1927-8",{"mag":1108,"pmc":1109,"openalex":1110,"pm":1111,"doi":1112},"2893481706","6245662","W2893481706","30259128","10.1007\u002Fs00702-018-1927-8",{"id":18,"text":1114,"url":1115,"identifiers":1116},"Ebadi, 2006, Therapeutic efficacy of selegiline in neurodegenerative disorders and neurological diseases, Curr Drug Targets, 7, 1513, 10.2174\u002F1389450110607011513","https:\u002F\u002Fdoi.org\u002F10.2174\u002F1389450110607011513",{"mag":1117,"openalex":1118,"pm":1119,"doi":1120},"2032534793","W2032534793","17100591","10.2174\u002F1389450110607011513",{"id":1122,"text":1123,"url":1124,"identifiers":1125},"3f29d5b0-1201-4240-8d25-5d98e5601348","Mallajosyula, 2009, Metabolic control analysis in a cellular model of elevated MAO-B: relevance to Parkinson's disease, Neurotox Res, 16, 186, 10.1007\u002Fs12640-009-9032-2","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs12640-009-9032-2",{"doi":1126},"10.1007\u002Fs12640-009-9032-2",{"id":18,"text":1128,"url":1129,"identifiers":1130},"Bach, 1988, cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties, Proc Natl Acad Sci USA, 85, 4934, 10.1073\u002Fpnas.85.13.4934","https:\u002F\u002Fdoi.org\u002F10.1073\u002Fpnas.85.13.4934",{"mag":1131,"pmc":1132,"openalex":1133,"pm":1134,"doi":1135},"2134996660","280552","W2134996660","3387449","10.1073\u002Fpnas.85.13.4934",{"id":18,"text":1137,"url":1138,"identifiers":1139},"Bai, 2005, Molecular cloning and characterization of monoamine oxidase A and B genes in pig, DNA Seq, 16, 161, 10.1080\u002F10425170500097925","https:\u002F\u002Fdoi.org\u002F10.1080\u002F10425170500097925",{"mag":1140,"openalex":1141,"pm":1142,"doi":1143},"2041101901","W2041101901","16147870","10.1080\u002F10425170500097925",{"id":18,"text":1145,"url":1146,"identifiers":1147},"Hashizume, 2003, Molecular cloning of canine monoamine oxidase subtypes A (MAOA) and B (MAOB) cDNAs and their expression in the brain, J Vet Med Sci, 65, 893, 10.1292\u002Fjvms.65.893","https:\u002F\u002Fdoi.org\u002F10.1292\u002Fjvms.65.893",{"mag":1148,"openalex":1149,"pm":1150,"doi":1151},"1993179092","W1993179092","12951422","10.1292\u002Fjvms.65.893",{"id":18,"text":1153,"url":1154,"identifiers":1155},"Kwan, 1992, cDNA cloning and sequencing of rat monoamine oxidase A: comparison with the human and bovine enzymes, Comp Biochem Physiol B, 102, 143, 10.1016\u002F0305-0491(92)90286-Z","https:\u002F\u002Fdoi.org\u002F10.1016\u002F0305-0491(92)90286-z",{"mag":1156,"openalex":1157,"pm":1158,"doi":1159},"2048785930","W2048785930","1526120","10.1016\u002F0305-0491(92)90286-z",{"id":18,"text":1161,"url":1162,"identifiers":1163},"Ito, 1988, Molecular cloning of a cDNA for rat liver monoamine oxidase B, Biochem Biophys Res Commun, 157, 970, 10.1016\u002FS0006-291X(88)80969-0","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fs0006-291x(88)80969-0",{"mag":1164,"openalex":1165,"pm":1166,"doi":1167},"1975957542","W1975957542","2974701","10.1016\u002Fs0006-291x(88)80969-0",{"id":1169,"text":1170,"url":1171,"identifiers":1172},"17ef978a-bbc0-4ccd-b265-97c125cfc8b7","Wang, 2008, Identification, expression and tissue distribution of a renalase homologue from mouse, Mol Biol Rep, 35, 613, 10.1007\u002Fs11033-007-9131-1","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs11033-007-9131-1",{"doi":1173},"10.1007\u002Fs11033-007-9131-1",{"id":18,"text":1175,"url":1176,"identifiers":1177},"Setini, 2005, Molecular characterization of monoamine oxidase in zebrafish (Danio rerio), Comp Biochem Physiol B Biochem Mol Biol, 140, 153, 10.1016\u002Fj.cbpc.2004.10.002","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.cbpc.2004.10.002",{"mag":1178,"openalex":1179,"pm":1180,"doi":1181},"2091886825","W2091886825","15621520","10.1016\u002Fj.cbpc.2004.10.002",{"id":18,"text":1183,"url":1184,"identifiers":1185},"Orsi, 2011, Overview of the marmoset as a model in nonclinical development of pharmaceutical products, Regul Toxicol Pharmacol, 59, 19, 10.1016\u002Fj.yrtph.2010.12.003","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.yrtph.2010.12.003",{"mag":1186,"pmc":1187,"openalex":1188,"pm":1189,"doi":1190},"1979534167","7126225","W1979534167","21156195","10.1016\u002Fj.yrtph.2010.12.003",{"id":18,"text":1192,"url":18,"identifiers":1193},"Chiueh, 1984, Neurochemical and behavioral effects of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) in rat, Guinea pig, and monkey, Psychopharmacol Bull, 20, 548",{},{"id":18,"text":1195,"url":18,"identifiers":1196},"Willoughby, 1988, Monoamine oxidase activity and distribution in marmoset brain: implications for MPTP toxicity, Neurosci Lett, 90, 100, 10.1016\u002F0304-3940(88)90794-X",{"doi":1197},"10.1016\u002F0304-3940(88)90794-X",{"id":18,"text":1199,"url":1200,"identifiers":1201},"Willoughby, 1988, Histochemical localisation of monoamine oxidase A and B in rat brain, J Neural Transm, 74, 29, 10.1007\u002FBF01243573","https:\u002F\u002Fdoi.org\u002F10.1007\u002Fbf01243573",{"mag":1202,"openalex":1203,"pm":1204,"doi":1205},"2090761972","W2090761972","3171572","10.1007\u002Fbf01243573",{"id":1207,"text":1208,"url":1209,"identifiers":1210},"aee8d603-8167-4844-8c9b-9c30f6060ff4","Kupsch, 2001, Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline, J Neural Transm, 108, 985, 10.1007\u002Fs007020170018","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs007020170018",{"doi":1211},"10.1007\u002Fs007020170018",{"id":1213,"text":1214,"url":1215,"identifiers":1216},"62504a97-3f74-4707-a862-db7598da9995","Nomoto, 1993, A selective MAOB inhibitor Ro19-6327 potentiates the effects of levodopa on parkinsonism induced by MPTP in the common marmoset, Neuropharmacology, 32, 473, 10.1016\u002F0028-3908(93)90172-Y","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002F002839089390172Y",{"doi":1217},"10.1016\u002F0028-3908(93)90172-y",{"id":18,"text":1219,"url":1220,"identifiers":1221},"Alia-Klein, 2008, Brain monoamine oxidase A activity predicts trait aggression, J Neurosci, 28, 5099, 10.1523\u002FJNEUROSCI.0925-08.2008","https:\u002F\u002Fdoi.org\u002F10.1523\u002Fjneurosci.0925-08.2008",{"mag":1222,"pmc":1223,"openalex":1224,"pm":1225,"doi":1226},"2159198897","2430409","W2159198897","18463263","10.1523\u002Fjneurosci.0925-08.2008",{"id":18,"text":1228,"url":1229,"identifiers":1230},"Uehara, 2015, Activation and deactivation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by cytochrome P450 enzymes and flavin-containing monooxygenases in common marmosets (Callithrix jacchus), Drug Metab Dispos, 43, 735, 10.1124\u002Fdmd.115.063594","http:\u002F\u002Fdx.doi.org\u002F10.1124\u002Fdmd.115.063594",{"doi":1231},"10.1124\u002Fdmd.115.063594",{"id":18,"text":1233,"url":18,"identifiers":1234},"Uehara, 2019",{},{"id":1236,"text":1237,"url":1238,"identifiers":1239},"efaf79c3-9521-4df8-a157-fc81105f959d","Shimamoto, 2013, Selection of suitable reference genes for mRNA quantification studies using common marmoset tissues, Mol Biol Rep, 40, 6747, 10.1007\u002Fs11033-013-2791-0","http:\u002F\u002Flink.springer.com\u002F10.1007\u002Fs11033-013-2791-0",{"doi":1240},"10.1007\u002Fs11033-013-2791-0",{"id":18,"text":1242,"url":1243,"identifiers":1244},"Grimsby, 1991, Human monoamine oxidase A and B genes exhibit identical exon-intron organization, Proc Natl Acad Sci U S A, 88, 3637, 10.1073\u002Fpnas.88.9.3637","https:\u002F\u002Fdoi.org\u002F10.1073\u002Fpnas.88.9.3637",{"mag":1245,"pmc":1246,"openalex":1247,"pm":1248,"doi":1249},"2024298846","51507","W2024298846","2023912","10.1073\u002Fpnas.88.9.3637",{"id":18,"text":1251,"url":1252,"identifiers":1253},"Son, 2008, Structure of human monoamine oxidase A at 2.2-A resolution: the control of opening the entry for substrates\u002Finhibitors, Proc Natl Acad Sci U S A, 105, 5739, 10.1073\u002Fpnas.0710626105","http:\u002F\u002Fdx.doi.org\u002F10.1073\u002Fpnas.0710626105",{"doi":1254},"10.1073\u002Fpnas.0710626105",{"id":1256,"text":1257,"url":1258,"identifiers":1259},"21a17eb9-1a98-4f15-a92c-8a79921c8a39","Binda, 2004, Crystal structure of human monoamine oxidase B, a drug target enzyme monotopically inserted into the mitochondrial outer membrane, FEBS Lett, 564, 225, 10.1016\u002FS0014-5793(04)00209-1","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0014579304002091",{"doi":1260},"10.1016\u002Fs0014-5793(04)00209-1",{"id":18,"text":1262,"url":1263,"identifiers":1264},"Grimsby, 1990, Tissue distribution of human monoamine oxidase A and B mRNA, J Neurochem, 55, 1166, 10.1111\u002Fj.1471-4159.1990.tb03121.x","https:\u002F\u002Fdoi.org\u002F10.1111\u002Fj.1471-4159.1990.tb03121.x",{"mag":1265,"openalex":1266,"pm":1267,"doi":1268},"2095451361","W2095451361","2398352","10.1111\u002Fj.1471-4159.1990.tb03121.x",{"id":18,"text":1270,"url":1271,"identifiers":1272},"Tong, 2013, Distribution of monoamine oxidase proteins in human brain: implications for brain imaging studies, J Cerebr Blood Flow Metabol, 33, 863, 10.1038\u002Fjcbfm.2013.19","https:\u002F\u002Fdoi.org\u002F10.1038\u002Fjcbfm.2013.19",{"mag":1273,"pmc":1274,"openalex":1275,"pm":1276,"doi":1277},"1972899609","3677103","W1972899609","23403377","10.1038\u002Fjcbfm.2013.19",{"id":18,"text":1279,"url":1280,"identifiers":1281},"Tong, 2017, Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders, Brain, 140, 2460, 10.1093\u002Fbrain\u002Fawx172","https:\u002F\u002Fdoi.org\u002F10.1093\u002Fbrain\u002Fawx172",{"mag":1282,"pmc":1283,"openalex":1284,"pm":1285,"doi":1286},"2738881219","6669411","W2738881219","29050386","10.1093\u002Fbrain\u002Fawx172",{"id":18,"text":1288,"url":18,"identifiers":1289},"Walker, 1971, The covalently-bound flavin of hepatic monoamine oxidase. 2. Identification and properties of cysteinyl riboflavin, Eur J Biochem, 24, 328, 10.1111\u002Fj.1432-1033.1971.tb19690.x",{"doi":1290},"10.1111\u002Fj.1432-1033.1971.tb19690.x",{"id":18,"text":1292,"url":1293,"identifiers":1294},"Kearney, 1971, The covalently-bound flavin of hepatic monoamine oxidase. 1. Isolation and sequence of a flavin peptide and evidence for binding at the 8alpha position, Eur J Biochem, 24, 321, 10.1111\u002Fj.1432-1033.1971.tb19689.x","https:\u002F\u002Fdoi.org\u002F10.1111\u002Fj.1432-1033.1971.tb19689.x",{"mag":1295,"openalex":1296,"pm":1297,"doi":1298},"1577728072","W1577728072","4333601","10.1111\u002Fj.1432-1033.1971.tb19689.x",{"id":18,"text":1300,"url":18,"identifiers":1301},"Wu, 1993, Site-directed mutagenesis of monoamine oxidase A and B: role of cysteines, Mol Pharmacol, 43, 888",{},{"id":18,"text":1303,"url":1304,"identifiers":1305},"Gottowik, 1993, Characterisation of wild-type and mutant forms of human monoamine oxidase A and B expressed in a mammalian cell line, FEBS Lett, 317, 152, 10.1016\u002F0014-5793(93)81512-X","https:\u002F\u002Fdoi.org\u002F10.1016\u002F0014-5793(93)81512-x",{"mag":1306,"openalex":1307,"pm":1308,"doi":1309},"1981626891","W1981626891","8428624","10.1016\u002F0014-5793(93)81512-x",{"id":18,"text":1311,"url":1312,"identifiers":1313},"Kirksey, 1998, Arginine-42 and threonine-45 are required for FAD incorporation and catalytic activity in human monoamine oxidase B, Biochemistry, 37, 12360, 10.1021\u002Fbi9806910","https:\u002F\u002Fdoi.org\u002F10.1021\u002Fbi9806910",{"mag":1314,"openalex":1315,"pm":1316,"doi":1317},"1983386009","W1983386009","9724550","10.1021\u002Fbi9806910",{"id":18,"text":1319,"url":18,"identifiers":1320},"Kwan, 1995, Characterization of a dinucleotide-binding site in monoamine oxidase B by site-directed mutagenesis, Arch Biochem Biophys, 316, 385, 10.1006\u002Fabbi.1995.1051",{"doi":1321},"10.1006\u002Fabbi.1995.1051",{"id":18,"text":1323,"url":1324,"identifiers":1325},"Zhou, 1995, Mutagenesis at a highly conserved tyrosine in monoamine oxidase B affects FAD incorporation and catalytic activity, Biochemistry, 34, 9526, 10.1021\u002Fbi00029a029","https:\u002F\u002Fdoi.org\u002F10.1021\u002Fbi00029a029",{"mag":1326,"openalex":1327,"pm":1328,"doi":1329},"1987684118","W1987684118","7626622","10.1021\u002Fbi00029a029",{"id":1331,"createTime":1332,"updateTime":1333,"relativeEntities":1334,"slug":1335,"properties":1336,"entityType":174,"verifyStatus":175,"verifyTime":1333,"verifyNote":177,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":1343,"fullTextUrl":18,"authors":1344,"publicationType":253,"publisherRelationship":1488,"citationCount":18,"citationInfo":18,"publishDate":1521,"publishYear":1522,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":289},"3d5f5486-fbee-448b-a589-9e5d4b08ade5","2024-01-18T16:41:43.336+00:00","2025-01-31T23:44:08.688+00:00",[],"Rifampin-enhances-cytochrome-P450-CYP-2B6-mediated-efavirenz-8-hydroxylation-in-healthy-volunteers",{"references":1337,"title":1339,"doi":1341},{"VOID":1338},"Ekins, 1999, The role of CYP2B6 in human xenobiotic metabolism, Drug Metab Rev, 31, 719, 10.1081\u002FDMR-100101942\nHodgson, 2007, The importance of cytochrome P450 2B6 in the human metabolism of environmental chemicals, Pharmacol Ther, 113, 420, 10.1016\u002Fj.pharmthera.2006.10.002\nWang, 2008, CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme, Curr Drug Metab, 9, 598, 10.2174\u002F138920008785821710\nMo, 2009, Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6, Curr Drug Metab, 10, 730, 10.2174\u002F138920009789895534\nTurpeinen, 2012, Cytochrome P450 2B6: function, genetics, and clinical relevance, Drug Metabol Drug Interact, 27, 185, 10.1515\u002Fdmdi-2012-0027\nZanger, 2013, Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance, Front Genet, 4, 1, 10.3389\u002Ffgene.2013.00024\nZanger, 2007, Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance, Pharmacogenomics, 8, 743, 10.2217\u002F14622416.8.7.743\nLi, 2012, Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV\u002FAIDS treatment, Pharmacogenomics, 13, 555, 10.2217\u002Fpgs.11.160\nTurpeinen, 2006, The functional role of CYP2B6 in human drug metabolism: substrates and inhibitors in vitro, in vivo and in silico, Curr Drug Metab, 7, 705, 10.2174\u002F138920006778520633\nFaucette, 2000, Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity, Drug Metab Dispos, 28, 1222\nXu, 2007, Stereoselective analysis of hydroxybupropion and application to drug interaction studies, Chirality, 19, 163, 10.1002\u002Fchir.20356\nKirchheiner, 2003, Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6, Pharmacogenetics, 13, 619, 10.1097\u002F00008571-200310000-00005\nSkarydova, 2014, Deeper insight into the reducing biotransformation of bupropion in the human liver, Drug Metab Pharmacokinet, 29, 177, 10.2133\u002Fdmpk.DMPK-13-RG-051\nChen, 2010, The in vitro metabolism of bupropion revisited: concentration dependent involvement of cytochrome P450 2C19, Xenobiotica, 40, 536, 10.3109\u002F00498254.2010.492880\nKharasch, 2008, Stereoselective bupropion hydroxylation as an in vivo phenotypic probe for cytochrome P4502B6 (CYP2B6) activity, J Clin Pharmacol, 48, 464, 10.1177\u002F0091270008314254\nWard, 2003, The cytochrome P4502B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV\u002FAIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity, J Pharmacol Exp Ther, 306, 287, 10.1124\u002Fjpet.103.049601\nOgburn, 2010, Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 (CYP) 2A6 as the principal catalyst of efavirenz 7-hydroxylation, Drug Metab Dispos, 38, 1218, 10.1124\u002Fdmd.109.031393\nDesta, 2007, Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro, Pharmacogenomics, 8, 547, 10.2217\u002F14622416.8.6.547\nMutlib, 1999, Identification and characterization of efavirenz metabolites by liquid chromatography\u002Fmass spectrometry and high field NMR: species differences in the metabolism of efavirenz, Drug Metab Dispos, 27, 1319\nTsuchiya, 2004, Homozygous CYP2B6*6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens, Biochem Biophys Res Commun, 319, 1322, 10.1016\u002Fj.bbrc.2004.05.116\nHaas, 2004, Pharmacogenetics of efavirenz and central nervous system side effects: an adult AIDS clinical trials group study, AIDS, 18, 2391\n2012\n2012\nRae, 2001, Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays, J Pharmacol Exp Ther, 299, 849\nFaucette, 2004, Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers, Drug Metab Dispos, 32, 348, 10.1124\u002Fdmd.32.3.348\nKharasch, 2004, Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone, Clin Pharmacol Ther, 76, 250, 10.1016\u002Fj.clpt.2004.05.003\nNoppers, 2011, Effect of rifampicin on S-ketamine and S-norketamine plasma concentrations in healthy volunteers after intravenous S-ketamine administration, Anesthesiology, 114, 1435, 10.1097\u002FALN.0b013e318218a881\nLopez-Cortes, 2002, Pharmacokinetic interactions between efavirenz and rifampicin in HIV- infected patients with tuberculosis, Clin Pharmacokinet, 41, 681, 10.2165\u002F00003088-200241090-00004\nCohen, 2009, Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G > T polymorphism on efavirenz concentrations in adults in South Africa, Antivir Ther, 14, 687, 10.1177\u002F135965350901400502\nDooley, 2015, Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection, J Infect Dis, 211, 197, 10.1093\u002Finfdis\u002Fjiu429\nKwara, 2011, Paradoxically elevated efavirenz concentrations in HIV\u002Ftuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy, AIDS, 25, 388, 10.1097\u002FQAD.0b013e3283427e05\nMeyer zu Schwabedissen, 2012, Compartment-specific gene regulation of the CAR inducer efavirenz in vivo, Clin Pharmacol Ther, 92, 103, 10.1038\u002Fclpt.2012.34\nKoh, 2012, Estradiol induces cytochrome P450 2B6 expression at high concentrations: implication in estrogen-mediated gene regulation in pregnancy, Biochem Pharmacol, 84, 93, 10.1016\u002Fj.bcp.2012.03.016\nMcIlleron, 2012, Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines, Antimicrob Agents Chemother, 56, 3232, 10.1128\u002FAAC.05526-11\nKim, 2011, Rapid and simultaneous determination of efavirenz, 8-hydroxyefavirenz, and 8,14-dihydroxyefavirenz using LC–MS–MS in human plasma and application to pharmacokinetics in healthy volunteers, Chromatographia, 73, 263, 10.1007\u002Fs10337-010-1882-5\nBlievernicht, 2007, MALDI-TOF mass spectrometry for multiplex genotyping of CYP2B6 single-nucleotide polymorphisms, Clin Chem, 53, 24, 10.1373\u002Fclinchem.2006.074856\nLang, 2001, Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver, Pharmacogenetics, 11, 399, 10.1097\u002F00008571-200107000-00004\n2015\nYenny, 2011, Pharmacokinetic interaction between efavirenz and rifampicin in healthy volunteers, Int J Clin Pharmacol Ther, 49, 162, 10.5414\u002FCP201473\nJiang, 2013, Effects of clopidogrel and itraconazole on the disposition of efavirenz and its hydroxyl-metabolites: exploration of a novel CYP2B6 phenotyping index, Br J Clin Pharmacol, 75, 244, 10.1111\u002Fj.1365-2125.2012.04314.x\nLuetkemeyer, 2013, Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study, Clin Infect Dis, 57, 586, 10.1093\u002Fcid\u002Fcit246\nMcIlleron, 2013, Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype, AIDS, 27, 1933, 10.1097\u002FQAD.0b013e328360dbb4\nBoulle, 2008, Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy, JAMA, 300, 530, 10.1001\u002Fjama.300.5.530\nFriedland, 2006, Administration of efavirenz (600 mg\u002Fday) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV, J Antimicrob Chemother, 58, 1299, 10.1093\u002Fjac\u002Fdkl399\nManosuthi, 2009, A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study, Clin Infect Dis, 48, 1752, 10.1086\u002F599114\nNiemi, 2003, Pharmacokinetic interactions with rifampicin: clinical relevance, Clin Pharmacokinet, 42, 819, 10.2165\u002F00003088-200342090-00003\nMukonzo, 2009, A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans, Br J Clin Pharmacol, 68, 690, 10.1111\u002Fj.1365-2125.2009.03516.x\nLamba, 2003, Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression, J Pharmacol Exp Ther, 307, 906, 10.1124\u002Fjpet.103.054866\nHofmann, 2008, Aberrant splicing caused by single nucleotide polymorphism c.516G > T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver, J Pharmacol Exp Ther, 325, 284, 10.1124\u002Fjpet.107.133306\nBurger, 2006, Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism, Br J Clin Pharmacol, 61, 148, 10.1111\u002Fj.1365-2125.2005.02536.x\nNgaimisi, 2010, Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients, Clin Pharmacol Ther, 88, 676, 10.1038\u002Fclpt.2010.172",{"EN":1340},"Rifampin enhances cytochrome P450 (CYP) 2B6-mediated efavirenz 8-hydroxylation in healthy volunteers",{"VOID":1342},"10.1016\u002Fj.dmpk.2015.07.002","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS1347436715000427",[1345,1360,1375,1387,1404,1416,1428,1440,1452,1464,1476],{"id":1346,"sortIndex":373,"researcher":18,"roles":1347,"affiliations":1348,"properties":1357},"84ea4740-8ccf-48e0-ab61-8f2ad35eaf67",[183],[1349],{"id":18,"sortIndex":19,"affiliation":1350,"properties":18},{"id":1351,"createTime":1352,"updateTime":1352,"relativeEntities":1353,"slug":18,"properties":1354,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"be574ca8-f0db-468a-9180-de776e66f09c","2024-01-18T16:41:43.779+00:00",[],{"title":1355},{"VI":1356},"Indiana University School of Medicine, Department of Medicine, Division of Clinical Pharmacology, Indianapolis, IN 46202, USA",{"title":1358},{"VI":1359},"Todd C. Skaar",{"id":1361,"sortIndex":695,"researcher":18,"roles":1362,"affiliations":1363,"properties":1372},"b4002780-ff6a-4d5b-8b8d-8865bdedf6af",[183],[1364],{"id":18,"sortIndex":19,"affiliation":1365,"properties":18},{"id":1366,"createTime":1367,"updateTime":1367,"relativeEntities":1368,"slug":18,"properties":1369,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"a459865e-3ba1-4d55-af0d-abb772fce8e7","2024-01-18T16:41:44.071+00:00",[],{"title":1370},{"VI":1371},"Inje University College of Medicine, Inje University Busan Paik Hospital, Busan 614-735, Republic of Korea",{"title":1373},{"VI":1374},"Kwon-Bok Kim",{"id":1376,"sortIndex":56,"researcher":18,"roles":1377,"affiliations":1378,"properties":1384},"075d25c6-acd1-42e7-ad8a-b16b26600226",[183],[1379],{"id":18,"sortIndex":19,"affiliation":1380,"properties":18},{"id":1351,"createTime":1352,"updateTime":1352,"relativeEntities":1381,"slug":18,"properties":1382,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1383},{"VI":1356},{"title":1385},{"VI":1386},"Suzanne M. Lemler",{"id":1388,"sortIndex":807,"researcher":18,"roles":1389,"affiliations":1390,"properties":1401},"8926b340-5f63-4a97-92cd-1933ad3f12c0",[183],[1391],{"id":18,"sortIndex":19,"affiliation":1392,"properties":18},{"id":1393,"createTime":1394,"updateTime":1395,"relativeEntities":1396,"slug":1397,"properties":1398,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"4d397aaa-095d-4767-b274-1cc7ee312739","2024-01-01T08:29:53.542+00:00","2025-01-29T17:00:23.746+00:00",[],"Dr-Margarete-Fischer-Bosch-Institute-of-Clinical-Pharmacology-Stuttgart-Germany",{"title":1399},{"VI":1400},"Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany",{"title":1402},{"VI":1403},"Ulrich M. Zanger",{"id":1405,"sortIndex":844,"researcher":18,"roles":1406,"affiliations":1407,"properties":1413},"28c85494-2023-45eb-ba5b-328507d755d2",[183],[1408],{"id":18,"sortIndex":19,"affiliation":1409,"properties":18},{"id":1351,"createTime":1352,"updateTime":1352,"relativeEntities":1410,"slug":18,"properties":1411,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1412},{"VI":1356},{"title":1414},{"VI":1415},"David A. Flockhart",{"id":1417,"sortIndex":19,"researcher":18,"roles":1418,"affiliations":1419,"properties":1425},"4a37599c-eda2-4916-8347-5c41b1a7a5d6",[183],[1420],{"id":18,"sortIndex":19,"affiliation":1421,"properties":18},{"id":1351,"createTime":1352,"updateTime":1352,"relativeEntities":1422,"slug":18,"properties":1423,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1424},{"VI":1356},{"title":1426},{"VI":1427},"Doo-Yeoun Cho",{"id":1429,"sortIndex":307,"researcher":18,"roles":1430,"affiliations":1431,"properties":1437},"c807c659-dad4-407a-8381-2c10c0c7ec73",[183],[1432],{"id":18,"sortIndex":19,"affiliation":1433,"properties":18},{"id":1393,"createTime":1394,"updateTime":1395,"relativeEntities":1434,"slug":1397,"properties":1435,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1436},{"VI":1400},{"title":1438},{"VI":1439},"Julia Blievernicht",{"id":1441,"sortIndex":728,"researcher":18,"roles":1442,"affiliations":1443,"properties":1449},"d8f081d0-9808-4b0e-9b2b-49b3bde4cc27",[183],[1444],{"id":18,"sortIndex":19,"affiliation":1445,"properties":18},{"id":1366,"createTime":1367,"updateTime":1367,"relativeEntities":1446,"slug":18,"properties":1447,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1448},{"VI":1371},{"title":1450},{"VI":1451},"Jae-Gook Shin",{"id":1453,"sortIndex":144,"researcher":18,"roles":1454,"affiliations":1455,"properties":1461},"b5702cc9-c0c4-4e9a-af54-f4d1f60bc892",[183],[1456],{"id":18,"sortIndex":19,"affiliation":1457,"properties":18},{"id":1351,"createTime":1352,"updateTime":1352,"relativeEntities":1458,"slug":18,"properties":1459,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1460},{"VI":1356},{"title":1462},{"VI":1463},"Joan H.Q. Shen",{"id":1465,"sortIndex":782,"researcher":18,"roles":1466,"affiliations":1467,"properties":1473},"609ce451-69b9-4b36-9e86-9afd5153bf89",[183],[1468],{"id":18,"sortIndex":19,"affiliation":1469,"properties":18},{"id":1351,"createTime":1352,"updateTime":1352,"relativeEntities":1470,"slug":18,"properties":1471,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1472},{"VI":1356},{"title":1474},{"VI":1475},"Zeruesenay Desta",{"id":1477,"sortIndex":345,"researcher":18,"roles":1478,"affiliations":1479,"properties":1485},"e8461910-c158-4392-a0ab-f4bc56093a8d",[183],[1480],{"id":18,"sortIndex":19,"affiliation":1481,"properties":18},{"id":1351,"createTime":1352,"updateTime":1352,"relativeEntities":1482,"slug":18,"properties":1483,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1484},{"VI":1356},{"title":1486},{"VI":1487},"Lang Li",{"url":1343,"publisher":1489,"properties":1516},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1490,"slug":10,"properties":1491,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":1494,"manageAffiliations":1495,"indexDatabases":1496,"url":18,"thumbnailPath":18,"statistic":1511,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":1492,"title":1493},{"VOID":13},{"EN":15},[],[],[1497,1504],{"id":70,"indexDatabase":1498,"url":85,"indexYears":18,"academicFieldIds":1503,"indexDatabaseRanking":18},{"id":72,"createTime":73,"updateTime":74,"relativeEntities":1499,"label":1500,"description":1501,"key":81,"publicationTags":1502,"standard":18},[],{"EN":77,"VI":77},{"VI":79,"EN":80},[83,84],[87],{"id":89,"indexDatabase":1505,"url":102,"indexYears":103,"academicFieldIds":1510,"indexDatabaseRanking":108},{"id":91,"createTime":92,"updateTime":93,"relativeEntities":1506,"label":1507,"description":1508,"key":99,"publicationTags":1509,"standard":18},[],{"EN":96,"VI":96},{"EN":96,"VI":98},[101],[105,106,107],{"impactFactor":19,"impactFactorByYear":1512,"i10Index":116,"i10IndexLast5Year":19,"totalPublication":117,"totalPublicationByYear":1513,"totalCitation":132,"totalCitationByYear":1514,"totalCitationPerPublication":145,"totalCitationPerPublicationByYear":1515,"hindexLast5Year":116,"hindex":116},{"2012":111,"2013":112,"2014":113,"2015":114,"2019":115},{"2002":119,"2003":120,"2004":121,"2005":121,"2006":122,"2007":119,"2008":119,"2009":123,"2010":124,"2011":124,"2012":125,"2013":126,"2014":127,"2015":123,"2016":124,"2017":128,"2018":129,"2019":129,"2020":127,"2021":125,"2022":130,"2023":131,"2024":56},{"2003":134,"2004":135,"2005":136,"2006":137,"2007":138,"2008":139,"2009":140,"2011":141,"2012":142,"2013":143,"2018":144},{"2003":147,"2004":148,"2005":149,"2006":150,"2007":151,"2008":152,"2009":153,"2011":154,"2012":151,"2013":155,"2018":156},{"volume":1517,"pages":1519},{"VOID":1518},"31",{"VOID":1520},"107-116","2016-04-01",2016,{"id":1524,"createTime":1525,"updateTime":1526,"relativeEntities":1527,"slug":1528,"properties":1529,"entityType":174,"verifyStatus":175,"verifyTime":1526,"verifyNote":177,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":1536,"fullTextUrl":18,"authors":1537,"publicationType":253,"publisherRelationship":1582,"citationCount":18,"citationInfo":18,"publishDate":1615,"publishYear":1616,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":289},"3c9b323b-979f-4f6e-84a4-163b70b458e6","2024-02-11T02:51:25.451+00:00","2024-12-07T23:43:36.865+00:00",[],"Role-and-Relevance-of-PEPT2-in-Drug-Disposition-Dynamics-and-Toxicity",{"references":1530,"title":1532,"doi":1534},{"VOID":1531},"Daniel, 2004, The proton oligopeptide cotransporter family SLC15 in physiology and pharmacology, Pflugers Arch., 447, 610, 10.1007\u002Fs00424-003-1101-4\nHerrera-Ruiz, 2002, Current perspectives on established and putative mammalian oligopeptide transporters, J. Pharm. Sci., 92, 691, 10.1002\u002Fjps.10303\nFei, 1994, Expression cloning of a mammalian proton-coupled oligopeptide transporter, Nature (Lond), 368, 563, 10.1038\u002F368563a0\nLui, 1995, Molecular cloning of PEPT2, a new member of the H +\u002Fpeptide cotransporter family from human kidney, Biochem. Biophys. Acta., 1235, 461, 10.1016\u002F0005-2736(95)80036-F\nYamashita, 1997, Cloning and functional expression of a brain peptide\u002Fhistidine transporter, J Biol. Chem., 272, 10205, 10.1074\u002Fjbc.272.15.10205\nSakata, 2001, Cloning of a lymphatic peptide\u002Fhistidine transporter, J. Biochem., 356, 53, 10.1042\u002F0264-6021:3560053\nBotka, 2000, Human proton\u002Foligopeptide transporter (POT) genes: identification of putative human genes using bioinformatics, AAPS Pharm. Sci., 2, 1, 10.1208\u002Fps020216\nRubio-Aliaga, 2002, Mammalian peptide transporters as targets for drug delivery, Trends pharmac. Sci., 23, 434, 10.1016\u002FS0165-6147(02)02072-2\nOgihara, 1996, Immunolocalization of H + \u002Fpeptide cotransporter in rat digestive tract, Biochem. Biophys. Res. Commun., 220, 848, 10.1006\u002Fbbrc.1996.0493\nGroneberg, 2001, Intestinal peptide transport: ex vivo uptake studies and localization of peptide carrier PEPT1, Am. J. Physiol. Gastrointest. Liver Physiol., 281, G697, 10.1152\u002Fajpgi.2001.281.3.G697\nShen, 1999, Localization of PEPT1 and PEPT2 proton-coupled oligopeptide transporter mRNA and protein in rat kidney, Am. J. Physiol., 276, F658\nLiang, 1995, Human intestinal H + \u002Fpeptide cotransporter, J. Biol. Chem., 270, 6456, 10.1074\u002Fjbc.270.12.6456\nBoll, 1996, Expression cloning and functional characterization of the kidney cortex high-affinity proton-coupled peptide transporter, Proc. Natl. Acad. Sci. USA, 93, 284, 10.1073\u002Fpnas.93.1.284\nDöring, 1998, Delta-aminolevulinic acid transport by intestinal and renal peptide transporters and its physiological and clinical implications, J Clin. Invest., 101, 2761, 10.1172\u002FJCI1909\nBerger, 1999, Distribution of peptide transporter PEPT2 mRNA in the rat nervous system, Anat. Embryol., 199, 439, 10.1007\u002Fs004290050242\nShen, 2004, Immunolocalization of the proton-coupled oligopeptide transporter PEPT2 in developing rat brain, Mol. Pharm., 1, 248, 10.1021\u002Fmp049944b\nNovotny, 2000, Mechanisms of 5-aminolevulinic acid uptake at the choroid plexus, J. Neurochem., 75, 321, 10.1046\u002Fj.1471-4159.2000.0750321.x\nShu, 2002, Role of PEPT2 in peptide\u002Fmimetic trafficking at the blood-cerebral fluid barrier: studies in rat choroid plexus epithelial cells in primary culture, J. Pharmacol. Exp. Ther., 301, 820, 10.1124\u002Fjpet.301.3.820\nTeuscher, 2000, Functional evidence for the presence of PEPT2 in rat choroid plexus: Studies with glycylsarcosine, J. Pharmacol. Exp. Ther., 294, 494\nTeuscher, 2001, PEPT2-mediated uptake of neuropeptides in rat choroid plexus, Pharm. Res., 18, 807, 10.1023\u002FA:1011088413043\nGroneberg, 2001, Expression of PEPT2 peptide transporter mRNA and protein in glial cells of rat dorsal root ganglia, Neurosci. Lett., 304, 181, 10.1016\u002FS0304-3940(01)01794-3\nGroneberg, 2001, Localization of the peptide transporter PEPT2 in the lung: implications for pulmonary oligopeptide uptake, Am. J. Pathol., 158, 707, 10.1016\u002FS0002-9440(10)64013-8\nOcheltree, 2005, Role and relevance of peptide transporter 2 (PEPT2) in the kidney and choroid plexus: in vivo studies with glycylsarcosine in wild-type and PEPT2 knockout mice, J. Pharmacol. Exp. Ther., 35, 240, 10.1124\u002Fjpet.105.089359\nShen, 2007, Impact of genetic knockout of PEPT2 on cefadroxil pharmacokinetics, renal tubular reabsorption, and brain penetration in mice, Drug Metab. Dispos., 35, 1209, 10.1124\u002Fdmd.107.015263\nSmith, 2004, Peptide and peptide analog transport systems at the blood-CSF barrier, Adv. Drug Deliv. Rev., 56, 1765, 10.1016\u002Fj.addr.2004.07.008\nOcheltree, 2003, Preliminary investigation into the expression of proton-coupled oligopeptide transporters in neural retina and retinal pigment epithelium (RPE): lack of functional activity in RPE plasma membranes, Pharm. Res., 20, 1364, 10.1023\u002FA:1025741723724\nHu, 2007, Peptide transporter 2 (PEPT2) expression in brain protects against 5-aminolevulinic acid neurotoxicity, J. Neurochem., 103, 2058, 10.1111\u002Fj.1471-4159.2007.04905.x\nShen, 2003, Targeted disruption of the PEPT2 gene markedly reduces dipeptide uptake in the choroid plexus, J. Biol. Chem., 278, 4786, 10.1074\u002Fjbc.M207397200\nCourtieu, 1983, Compared sensitivities of 532 bacterial strains to six cephalosporins, Int. J. Clin. Pharmacol. Res., 3, 195\nAnderson, 2001, Disorders of heme biosynthesis: X-linked siderolblastic anemia and the porphyrias, 2991\nLindberg, 1999, Motor neuropathy in porphobilinogen deaminase-deficient mice imitates the peripheral neuropathy of human acute porphyria, J. Clin. Invest., 103, 1127, 10.1172\u002FJCI5986\nAlbers, 2004, Porphyric neuropathy, Muscle Nerve, 30, 410, 10.1002\u002Fmus.20137\nKlassen, 2006, Heavy metals and heavy-metal antagonists, 1753\nOcheltree, 2004, Role of PEPT2 in the choroid plexus uptake of glycylsarcosine and 5-aminolevulinic acid: studies in wild-type and null mice, Pharm. Res., 21, 1680, 10.1023\u002FB:PHAM.0000041465.89254.05\nAdhikari, 2006, 5-Aminolevulinate and 4,5-diox-ovalerate ions decrease GABAA receptor density in neuronal cells, synaptosomes and rat brain, Brain Res., 1093, 95, 10.1016\u002Fj.brainres.2006.03.103\nZhang, 2004, Comparison of human and monkey peptide transporters: PEPT1 and PEPT2, Mol. Pharm, 1, 201, 10.1021\u002Fmp0499712\nFei, 1998, Molecular and structural features of the proton-coupled oligopeptide transporter superfamily, Prog. Nucleic Acid Res. Mol. Biol., 58, 239, 10.1016\u002FS0079-6603(08)60038-0\nGanapathy, 1995, Differential recognition of β-lactam antibiotics by intestinal and renal peptide transporters, PEPT1 and PEPT2, J. Biol. Chem., 270, 25672, 10.1074\u002Fjbc.270.43.25672\nBiegel, 2006, The renal type H + \u002Fpeptide symporter PEPT2: structure-affinity relationships, Amino Acids, 31, 137, 10.1007\u002Fs00726-006-0331-0\nSugawara, 2000, Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2, J. Pharm. Sci., 89, 781, 10.1002\u002F(SICI)1520-6017(200006)89:6\u003C781::AID-JPS10>3.0.CO;2-7\nRamamoorthy, 1995, Proton\u002Fpeptide cotransporter (PEPT2) from human kidney: functional characterization and chromosomal localization, Biochim. et. Biophys. Acta., 1240, 1, 10.1016\u002F0005-2736(95)00178-7\nBahadurri, 2005, Functional characterization of the peptide transporter PEPT2 in primary cultures of human upper airway epithelium, Am. J. Resp. Cell Mol. Biol., 32, 319, 10.1165\u002Frcmb.2004-0322OC\nTerada, 2004, Genetic variant Arg57His in human H + \u002Fpeptide cotransporter 2 causes a complete loss of transport function, Biochem. Biophys. Res. Commun., 316, 416, 10.1016\u002Fj.bbrc.2004.02.063\nPinsonneault, 2004, Genetic variants of the human H+ \u002Fdipeptide transporter PEPT2: analysis of haplotype functions, J. Pharmacol. Exp. Ther., 311, 1088, 10.1124\u002Fjpet.104.073098",{"EN":1533},"Role and Relevance of PEPT2 in Drug Disposition, Dynamics, and Toxicity",{"VOID":1535},"10.2133\u002Fdmpk.23.236","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS1347436715301920",[1538,1555,1567],{"id":1539,"sortIndex":19,"researcher":18,"roles":1540,"affiliations":1541,"properties":1552},"11d64b5b-9436-45b0-ae9a-cc3581cca207",[183],[1542],{"id":18,"sortIndex":19,"affiliation":1543,"properties":18},{"id":1544,"createTime":1545,"updateTime":1546,"relativeEntities":1547,"slug":1548,"properties":1549,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"a5f1d05a-9fcc-45c6-907d-c1806139221b","2024-04-16T01:22:32.831+00:00","2025-01-27T04:42:23.637+00:00",[],"Department-of-Pharmaceutical-Sciences",{"title":1550},{"EN":1551},"Department of Pharmaceutical Sciences",{"title":1553},{"VI":1554},"Mohamed A. Kamal",{"id":1556,"sortIndex":56,"researcher":18,"roles":1557,"affiliations":1558,"properties":1564},"bdb36bed-7a0b-4eba-bc53-05ce3d048cd5",[183],[1559],{"id":18,"sortIndex":19,"affiliation":1560,"properties":18},{"id":1544,"createTime":1545,"updateTime":1546,"relativeEntities":1561,"slug":1548,"properties":1562,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1563},{"EN":1551},{"title":1565},{"VI":1566},"David E. Smith",{"id":1568,"sortIndex":144,"researcher":18,"roles":1569,"affiliations":1570,"properties":1579},"b249337b-7153-4c86-80f5-0610966e4a06",[183],[1571],{"id":18,"sortIndex":19,"affiliation":1572,"properties":18},{"id":1573,"createTime":1574,"updateTime":1574,"relativeEntities":1575,"slug":18,"properties":1576,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"6049e0a8-079d-48e2-99ff-986d4e7b925f","2024-02-11T02:51:25.505+00:00",[],{"title":1577},{"VI":1578},"Departments of Neurosurgery and Physiology, University of Michigan, U.S.A.",{"title":1580},{"VI":1581},"Richard F. Keep",{"url":1536,"publisher":1583,"properties":1610},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1584,"slug":10,"properties":1585,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":1588,"manageAffiliations":1589,"indexDatabases":1590,"url":18,"thumbnailPath":18,"statistic":1605,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":1586,"title":1587},{"VOID":13},{"EN":15},[],[],[1591,1598],{"id":70,"indexDatabase":1592,"url":85,"indexYears":18,"academicFieldIds":1597,"indexDatabaseRanking":18},{"id":72,"createTime":73,"updateTime":74,"relativeEntities":1593,"label":1594,"description":1595,"key":81,"publicationTags":1596,"standard":18},[],{"EN":77,"VI":77},{"VI":79,"EN":80},[83,84],[87],{"id":89,"indexDatabase":1599,"url":102,"indexYears":103,"academicFieldIds":1604,"indexDatabaseRanking":108},{"id":91,"createTime":92,"updateTime":93,"relativeEntities":1600,"label":1601,"description":1602,"key":99,"publicationTags":1603,"standard":18},[],{"EN":96,"VI":96},{"EN":96,"VI":98},[101],[105,106,107],{"impactFactor":19,"impactFactorByYear":1606,"i10Index":116,"i10IndexLast5Year":19,"totalPublication":117,"totalPublicationByYear":1607,"totalCitation":132,"totalCitationByYear":1608,"totalCitationPerPublication":145,"totalCitationPerPublicationByYear":1609,"hindexLast5Year":116,"hindex":116},{"2012":111,"2013":112,"2014":113,"2015":114,"2019":115},{"2002":119,"2003":120,"2004":121,"2005":121,"2006":122,"2007":119,"2008":119,"2009":123,"2010":124,"2011":124,"2012":125,"2013":126,"2014":127,"2015":123,"2016":124,"2017":128,"2018":129,"2019":129,"2020":127,"2021":125,"2022":130,"2023":131,"2024":56},{"2003":134,"2004":135,"2005":136,"2006":137,"2007":138,"2008":139,"2009":140,"2011":141,"2012":142,"2013":143,"2018":144},{"2003":147,"2004":148,"2005":149,"2006":150,"2007":151,"2008":152,"2009":153,"2011":154,"2012":151,"2013":155,"2018":156},{"volume":1611,"pages":1613},{"VOID":1612},"23",{"VOID":1614},"236-242","2008-01-01",2008,{"id":1618,"createTime":1619,"updateTime":1619,"relativeEntities":1620,"slug":18,"properties":1621,"entityType":174,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":1628,"fullTextUrl":18,"authors":1629,"publicationType":253,"publisherRelationship":1660,"citationCount":18,"citationInfo":18,"publishDate":1693,"publishYear":1694,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":289},"0a964a9a-b177-40cc-b8d1-80cbde4199e1","2024-01-08T23:41:58.672+00:00",[],{"references":1622,"title":1624,"doi":1626},{"VOID":1623},"Kusuhara, 2002, Role of transporters in the tissue-selective distribution and elimination of drugs: transporters in the liver, small intestine, brain and kidney, J. Control Release, 78, 43, 10.1016\u002FS0168-3659(01)00480-1\nKim, 2000, Transporters in drug disposition, Curr. Opin. Drug Discov. Develop., 3, 94\nZhang, 1998, Role of organic cation transporters in drug absorption and elimination, Ann. Rev. Pharmacol. Toxicol., 38, 431, 10.1146\u002Fannurev.pharmtox.38.1.431\nKoepsell, 1998, Organic cation transporters in intestine, kidney, liver, and brain, Ann. Rev. Physiol., 60, 243, 10.1146\u002Fannurev.physiol.60.1.243\nMeijer, 1999, Transport mechanisms for cationic drugs and proteins in kidney, liver and intestine: implication for drug interactions and cellspecific drug delivery, Nephrol. Dial. Transplant., 14, 1, 10.1093\u002Fndt\u002F14.suppl_4.1b\nHirohashi, 2000, ATP-dependent transport of bile salts by rat multidrug resistance-associated protein 3 (mrp3), J. Biol. Chem., 275, 2905, 10.1074\u002Fjbc.275.4.2905\nHirohashi, 1999, Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (MRP3), J. Biol. Chem., 274, 15181, 10.1074\u002Fjbc.274.21.15181\nGao, 2001, Organic anion transport across the chroid plexus, Microsc. Res. Tech., 52, 60, 10.1002\u002F1097-0029(20010101)52:1\u003C60::AID-JEMT8>3.0.CO;2-C\nSuzuki, 1999, Transporters for bile acids and organic anions, 387\nWhite, 2000, High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery, Annu. Rev. Pharmacol. Toxicol., 40, 133, 10.1146\u002Fannurev.pharmtox.40.1.133\nRoberts, 2001, High-throughput screening approaches for investigating drug metabolism and pharmacokinetics, Xenobiotica, 31, 557, 10.1080\u002F00498250110060978\nKusuhara, 2001, Drug-drug interactions involving the membrane transport process, 123\nAyrton, 2001, Role of transport proteins in drug absorption, distribution and excretion, Xenobiotica, 31, 469, 10.1080\u002F00498250110060969\nDresser, 2001, Transporters involved in the elimination of drugs in the kidney: oraganic anion transporters and organic cation transporters, J. Pharm. Sci., 90, 397, 10.1002\u002F1520-6017(200104)90:4\u003C397::AID-JPS1000>3.0.CO;2-D\nMeier, 1997, Substrate specificity of sinusoidal bile acid and organic anion uptake systems in rat and human liver, Hepatology, 26, 1667, 10.1002\u002Fhep.510260641\nHooiveld, 2001, Function and regulation of ATP-binding cassette transport proteins involved in hepatobiliary transport, Eur. J. Pharm. Sci., 12, 525, 10.1016\u002FS0928-0987(01)00101-4\nLee, 2001, Pharmacogenomics of drug transporters: the next drug delivery challenge, Adv. Drug Deliv. Rev., 50, S33, 10.1016\u002FS0169-409X(01)00186-7\nKullak-Ublick, 2001, Organic aniontransporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver, Gastroenterology, 120, 525, 10.1053\u002Fgast.2001.21176\nInui, 2000, Physiological and pharmacological implications of peptide transporters, PEPT1 and PEPT2, Nephrol. Dial. Transplant., 15, 11, 10.1093\u002Fndt\u002F15.suppl_6.11\nKonig, 2000, Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide, J. Biol. Chem., 275, 23161, 10.1074\u002Fjbc.M001448200\nTamai, 2000, Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family, Biochem. Biophys. Res. Commun., 273, 251, 10.1006\u002Fbbrc.2000.2922\nKusuhara, 1998, The role of P-glycoprotein and canalicular multispecific organic anion transporter (cMOAT) in the hepatobiliary excretion of drugs, J. Pharm. Sci., 87, 1025, 10.1021\u002Fjs970100b\nBorst, 1999, The multidrug resistance protein family, Biochim. Biophys. Acta., 1461, 347, 10.1016\u002FS0005-2736(99)00167-4\nGreiner, 1999, The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin, J. Clin. Invest., 104, 147, 10.1172\u002FJCI6663\nMasuda, 2000, Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a livingdonor small bowel recipient, Clin. Pharmacol. Ther., 68, 93, 10.1067\u002Fmcp.2000.107912\nIto, 1998, Functional analysis of a canalicular multispecific organic anion transporter cloned from rat liver, J. Biol. Chem., 273, 1684, 10.1074\u002Fjbc.273.3.1684\nIto, 1997, Molecular cloning of canalicular multispecific organic anion transporter defective in EHBR, Am. J. Physiol., 272, G16\nHirohashi, 2000, Functional and expression of multidrug resistance-associated protein family in human colon adenocarcinoma cells (Caco-2), J. Pharmacol. Exp. Ther., 292, 265\nGotoh, 2000, Involvement of an organic anion transporter (canalicular multispecific organic anion transporter\u002Fmutidrug resistance-associated protein 2) in gastrointestinal secretion of glutathione conjugates in rats, J. Pharmacol. Exp. Ther., 292, 433\nOkudaira, 2000, A study of the intestinal absorption of and ester type prodrug, ME3229 in rats: active efflux transport as a cause of poor bioavailability of the active drug, J. Pharmacol. Exp. Ther., 294, 580\nOkudaira, 2000, Polarized efflux of mono- and diacid metabolites of ME3229, an ester-type prodrug of a glycoprotein IIb\u002FIIIa receptor antagonist, in rat small intestine, J. Pharmacol. Exp. Ther., 295, 717\nMaliepaard, 2001, Subcellular localization and distribution of the breast cancer resistance protein transporter in nomal human tissues, Cancer Res., 61, 3458\nJonker, 2000, Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan, J. Natl. Cancer. Inst., 92, 1651, 10.1093\u002Fjnci\u002F92.20.1651\nSikic, 2000, Enhanced bioavailability of oral paclitaxel by valspodar (PSC833), an inhibitor of small bowel P-glycoprotein and cytochrome P450, Clin. Cancer Res., 6, 4580S\nYamazaki, 1996, Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics, Pharm. Res., 13, 497, 10.1023\u002FA:1016077517241\nHsiang, 1999, A novel human hepatic organic anion transporting polypeptide (OATP2), J. Biol. Chem., 274, 37161, 10.1074\u002Fjbc.274.52.37161\nNakanishi, 1997, Carrier-mediated transport of oligopeptides in the human fibrosarcoma cell line HT1080, Cancer. Res., 58, 4118\nNakanishi, 2000, Cancer cell-targeted drug delivery utilizing oligopeptide transport activity, Int. J. Cancer, 88, 274, 10.1002\u002F1097-0215(20001015)88:2\u003C274::AID-IJC20>3.0.CO;2-5\nSuzuki, 1997, Role of efflux transport across the blood–brain barrier and blood-cerebrospinal fluid barrier on the disposition of xenobiotics in the central nervous system, Adv. Drug. Deliv. Rev., 25, 257, 10.1016\u002FS0169-409X(97)00503-6\nKusuhara, 2001, Efflux transport system for drugs at the blood–brain barrier and bloodcerebrospinal fluid barrier (Part 1, 2), Drug. Discov. Today, 6, 150, 10.1016\u002FS1359-6446(00)01632-9\nTamai, 2000, Transporter-mediated permea tion of drugs across the blood–brain barrier, J. Pharm. Sci., 89, 1371, 10.1002\u002F1520-6017(200011)89:11\u003C1371::AID-JPS1>3.0.CO;2-D\nSadeque, 2000, Increased drug delivery to the brain by P-glycoprotein inhibition, Clin. Pharmacol. Ther., 68, 231, 10.1067\u002Fmcp.2000.109156\nIshikawa, 1996, Coordinate induction of MRP\u002FGS-X pump and gammaglutamylcysteine synthetase by heavy metals in human leukemia cells, J. Biol. Chem., 271, 14981, 10.1074\u002Fjbc.271.25.14981\nKuo, 1998, Frequent coexpression of MRP\u002FGS-X pump and gammaglutamylcysteine synthetase mRNA in drug-resistant cells, untreated tumor cells, and normal mouse tissues, Biochem. Pharmacol., 55, 605, 10.1016\u002FS0006-2952(97)00494-2\nKool, 1999, MRP3 and organic anion transporter able to transport anticancer drugs, Proc. Natl. Acad. Sci. USA, 96, 6914, 10.1073\u002Fpnas.96.12.6914\nKonig, 1999, Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance, Biochim. Biophys. Acta., 1461, 377, 10.1016\u002FS0005-2736(99)00169-8\nKuwano, 1999, Multidrug resistance-associated protein subfamily transporters and drug resistance, Anticancer Drug. Des., 14, 123\nCole, 1998, Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP, Bioessays, 20, 931, 10.1002\u002F(SICI)1521-1878(199811)20:11\u003C931::AID-BIES8>3.0.CO;2-J\nDantzig, 2001, Reversal of multidrug resistance by the P-glycoprotein modulator, LY335989, from the bench to the clinic, Curr. Med. Chem., 8, 39, 10.2174\u002F0929867013373903\nMalingre, 2001, Coadministration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients, Br. J. Cancer, 84, 42, 10.1054\u002Fbjoc.2000.1543\nMistry, 2001, In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576, Cancer Res., 61, 749\nIshikawa, 2000, The human multidrug resistance-associated protein (MRP) gene family: from biological function to drug molecular design, Clin. Chem. Lab. Med., 38, 893, 10.1515\u002FCCLM.2000.130\nHuisman, 2000, Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors, AIDS, 14, 237, 10.1097\u002F00002030-200002180-00005\nLee, 1998, HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter, Biochemistry, 37, 3594, 10.1021\u002Fbi972709x\nHoetelmans, 1998, Sanctuary site in HIV-1 infection, Antivir. Ther., 3, 13\nTurriziani, 2000, May the drug transporter P-glycoprotein affect the antiviral activity of human immunodeficiency virus type 1 proteinase inhibitors?, Antimicrob. Agents Chemother., 44, 473, 10.1128\u002FAAC.44.2.473-474.2000\nSmit, 1999, Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure, J. Clin. Invest., 104, 1441, 10.1172\u002FJCI7963\nKim, 1998, The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors, J. Clin. Invest., 101, 289, 10.1172\u002FJCI1269\nChoo, 2000, Pharmacological inhibition of p-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes, Drug Metab. Dispos., 28, 655\nMerry, 1997, Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients, AIDS, 11, F29, 10.1097\u002F00002030-199704000-00001\nvan Praag, 2000, Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir, AIDS, 14, 1187, 10.1097\u002F00002030-200006160-00016\nSchinkel, 1994, Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood–brain barrier and to increased sensitivity to drugs, Cell, 77, 491, 10.1016\u002F0092-8674(94)90212-7\nJonker, 2001, Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene, Mol. Cell. Biol., 21, 5471, 10.1128\u002FMCB.21.16.5471-5477.2001\nWijnholds, 1997, Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein, Nat. Med., 3, 1275, 10.1038\u002Fnm1197-1275\nWijnholds, 2000, Multidrug resistance protein 1 protects the chroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier, J. Clin. Invest., 105, 279, 10.1172\u002FJCI8267\nSekine, 2000, The multispecific organic anion transporter (OAT) family, Pflugers Arch., 440, 337, 10.1007\u002Fs004240000297\nHosoyamada, 1999, Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney, Am. J. Physiol., 276, F122\nCihlar, 1999, The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1, Mol. Pharmacol., 56, 570, 10.1124\u002Fmol.56.3.570\nJung, 2001, Characterization of ochratoxin A transport by human organic anion transporters, Life Sci., 69, 2123, 10.1016\u002FS0024-3205(01)01296-6\nWada, 2000, Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs, J. Pharmacol. Exp. Ther., 294, 844\nJariyawat, 1999, The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1, J. Pharmacol. Exp. Ther., 290, 672\nCihlar, 2001, Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs, Nucleosides Nucleotides Nucleic Acids, 20, 641, 10.1081\u002FNCN-100002341\nCihlar, 2000, Fluorescence-based assay for the interaction of small molecules with the human renal organic anion transporter 1, Anal. Biochem., 283, 49, 10.1006\u002Fabio.2000.4633\nMulato, 2000, Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1, J. Pharmacol. Exp. Ther., 295, 10\nApiwattanakul, 1999, Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes, Mol. Pharmacol., 55, 847\nRowinsky, 1994, Phase I and Pharmacological study of novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin (CPT-11) ad ministered as a ninety-minute infusion every 3 weeks, Cancer Res., 54, 427\nAraki, 1993, Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11, Jpn. J. Cancer Res., 84, 697, 10.1111\u002Fj.1349-7006.1993.tb02031.x\nKanedam, 1990, Nonlinear pharmacokinetics of CPT-11 in rats, Cancer Res., 50, 1721\nChu, 1997, Multispecific organic anion transporter (cMOAT) is responsible for the bilialy excretion of the camptothecin derivative irinotecan, CPT-11, and its metabolites in rats, J. Pharmacol. Exp. Ther., 281, 304\nChu, 1997, Multiplicity of biliary excretion mechanisms for the camptothecin dericative irinotecan, CPT-11, and its metabolites in rats, Cancer Res., 57, 1934\nChu, 1998, Biliary excretion mechanism of CPT-11 and its metabolites in humans: Involvement of primary active transporters, Cancer Res., 58, 5137\nKeppler, 2000, Hepatic secretion of conjugated drugs and endogenous substance, Semin. Liver Dis., 20, 265, 10.1055\u002Fs-2000-9391\nKullak-Ublick, 2000, Hepatic transport of bile salts, Semin. Liver Dis., 20, 273, 10.1055\u002Fs-2000-9426\nInui, 2000, Cellular and molecular aspects of drug transport in the kidney, Kidney Int., 58, 944, 10.1046\u002Fj.1523-1755.2000.00251.x\nOguchi, 1993, Pharmacokinetics of temocapril and enalapril in patients with various degree of renal insufficiency, Clin. Pharmacokinet., 24, 421, 10.2165\u002F00003088-199324050-00006\nIshizuka, 1997, Temocaprilat, a novel angiotensin converting enzyme inhibitor, is excreted into bile via an ATP-dependent active transporter (cMOAT) that is deficient in Eisai hyper-biliruminemic mutant rats (EHBR), J. Pharmacol. Exp. Ther., 280, 1304\nIshizuka, 1999, Species differences in the transport activity for organic anions across the bile canalicular membrane, J. Pharmacol. Exp. Ther., 290, 1324\nKonig, 2000, A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane, Am. J. Physiol. Gastrointest. Liver Physiol., 278, G156, 10.1152\u002Fajpgi.2000.278.1.G156\nAbe, 1999, Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1, J. Biol. Chem., 274, 17159, 10.1074\u002Fjbc.274.24.17159\nKakyo, 1999, Molecular characterization and functional regulation of a novel rat liver-specific organic anion transporter rlst-1, Gastroenterology, 117, 770, 10.1016\u002FS0016-5085(99)70333-1\nZhang, 1997, Cloning and functional expression of a human liver organic cation transporter, Mol. Pharmacol., 51, 913, 10.1124\u002Fmol.51.6.913\nKovaril, 1999, Longitudinal assessment of a P-glycoprotein-mediated drug interaction of valspodar on digoxin, Clin. Pahrmacol. Ther., 66, 391, 10.1053\u002Fcp.1999.v66.a101462\nHedman, 1991, Digoxin-verapamil interaction: reduction of biliary but not renal digoxin clearance in humans, Clin. Pharmacol. Ther., 49, 256, 10.1038\u002Fclpt.1991.26\nHedman, 1990, Interactions in the renal and biliary elimination of digoxin: stereoselective difference between quinine and quinidine, Clin. Pharmacol. Ther., 47, 20, 10.1038\u002Fclpt.1990.3\nMuck, 1999, Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients, Clin. Pharmacol. Ther., 65, 251, 10.1016\u002FS0009-9236(99)70104-9\nSasaki, M., Suzuki, H., Ito, K., Abe, T. and Sugiyama, Y.: Transcellular transport of organic anions across double-transfected MDCK II cell monolayer expressing both human organic anion transporting polypeptide (OATP2\u002FSLC21A6) and multidrug resistance associated protein 2 (MRP2\u002FABCC2). J. Biol. Chem., in press.\nAlexandridis, 2000, Rhabdomyolysis due to combination therapy with cerivastatin and gemfibrozil, Am. J. Med., 109, 261, 10.1016\u002FS0002-9343(00)00514-3\nSoRelle, 2001, Baycol withdrawn from market, Circulation, 104, E9015\nSchwarz, 2000, P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans, Int. J. Clin. Pharmacol. Ther., 38, 161, 10.5414\u002FCPP38161\nSuzuki, 2000, Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine, Eur. J. Pharm. Sci., 12, 3, 10.1016\u002FS0928-0987(00)00178-0\nWacher, 2001, Active secretion and enterocytic drug metabolism barriers to drug absorption, Adv. Drug Deliv. Rev., 46, 89, 10.1016\u002FS0169-409X(00)00126-5\nCvetkovic, 1999, OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine, Drug Metab. Dispos., 27, 866\nBailey, 2001, Reduction of fexofenadine bioavailability by fruit juices [abstract], Clin. Pharmacol. Ther., 69, 21\nJohne, 1999, Pharmacokinetic interaction of digoxin with an herbal extract from St John’s wort, Clin. Pharmacol. Ther., 66, 338, 10.1053\u002Fcp.1999.v66.a101944\nDurr, 2000, St John’s wort induces intestinal P-glycoprotein\u002FMDR1 and intestinal and hepatic CYP3A4, Clin. Pharmacol. Ther., 68, 598, 10.1067\u002Fmcp.2000.112240\nFromm, 2000, The effect of rifampin treatment on intestinal expression of human MRP transporters, Am. J. Pathol., 157, 1575, 10.1016\u002FS0002-9440(10)64794-3\nSynold, 2001, The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux, Nature Med., 7, 584, 10.1038\u002F87912\nGeick, 2001, Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin, J. Biol. Chem., 276, 14581, 10.1074\u002Fjbc.M010173200\nMasuyama, 2001, The expression of pregnane X receptor and its target gene, cytochrome P450 3A1, in perinatal mouse, Mol. Cell Endocrinol., 172, 47, 10.1016\u002FS0303-7207(00)00395-6\nUeda, 2001, Inhibition of the bilialy excretion of methotrexate by probenecid in rats: Quantitative prediction of the interaction from in vitro data, J. Pharmacol. Exp. Ther., 297, 1036\nMayatepek, 2000, Two novel missense mutations of the OCTN2 gene (W283R and V446F) in a patient with primary systemic carnitine deficiency, Hum. Mutat., 15, 118, 10.1002\u002F(SICI)1098-1004(200001)15:1\u003C118::AID-HUMU28>3.0.CO;2-8\nIto, 2001, Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2\u002FcMOAT, in healthy Japanese subjects, Pharmacogenetics, 11, 175, 10.1097\u002F00008571-200103000-00008\nKerb, 2001, ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2, Pharmacogenetics, 2, 51, 10.1517\u002F14622416.2.1.51\nNezu, 1999, Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter, Nat. Genet., 21, 91, 10.1038\u002F5030\nHoffmeyer, 2000, Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo, Proc. Natl. Acad. Sci. USA, 97, 3473, 10.1073\u002Fpnas.97.7.3473\nCascorbi, 2001, Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transpsorter MDR1 gene in white subjects, Clin. Pharmacol. Ther., 69, 169, 10.1067\u002Fmcp.2001.114164\nAmeyaw, 2001, MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity, Pharmacogenetics, 11, 217, 10.1097\u002F00008571-200104000-00005\nKim, 2001, Identification of functionally variant MDR1 alleles among European Americans and African Americans, Clin. Pharmacol. Ther., 70, 189, 10.1067\u002Fmcp.2001.117412\nTirona, 2001, Polymorphisms in oatp-c. Identification of multiple allelic variants associated with altered transport activity among European- and African-americans, J. Biol. Chem., 276, 35669, 10.1074\u002Fjbc.M103792200\nAdachi, 2001, Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein, Pharm. Res., 18, 1660, 10.1023\u002FA:1013358126640\nYamazaki, 2001, In vitro substrate identification studies for P-glycoprotein-mediated transport: Species difference and predictability of in vivo results, J. Pharmacol. Exp. Ther., 296, 723\nPauli Magnus, 2001, Pglycoprotein-mediated transport of digitoxin, alphamethyldigoxin and beta-acetyldigoxin, Naunyn. Schmiedebergs. Arch. Pharmacol., 363, 337, 10.1007\u002Fs002100000354\nCui, 2001, Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCC2, Mol. Pharmacol., 60, 934, 10.1124\u002Fmol.60.5.934\nDoppenschmitt, 1998, Radioligand-binding assay employing P-glycoprotein-overexpressing cells: testing drug affinities to the secretory intestinal multidrug transporter, J. Pharm. Res., 15, 1001, 10.1023\u002FA:1011965707998\nWang, 2000, In vitro flow cytometry method to quantitatively assess inhibitors of P-glycoprotein, Drug Metab. Dispos., 28, 316\nEneroth, 2001, Evaluation of a vincristine resistant Caco-2 cell line for use in a calcein AM extrusion screening assay for P-glycoprotein interaction, Eur. J. Pharm. Sci., 12, 205, 10.1016\u002FS0928-0987(00)00117-2\nFernandes, 1998, Technological advances in high-throughput screening, Curr. Opin. Chem. Biol., 2, 597, 10.1016\u002FS1367-5931(98)80089-6\nPolli, 2001, Rational use of in vitro P-glycoprotein assays in drug discovery, J. Pharmacol. Exp. Ther., 299, 620\nSeelig, 2000, Structure-activity relationship of P-glycoprotein substrates and modifiers, Eur. J. Pharm. Sci., 12, 31, 10.1016\u002FS0928-0987(00)00177-9\nEkins, 2000, Progress in predicting human ADME parameters in silico, J. Pharmacol. Toxicol. Methods, 44, 251, 10.1016\u002FS1056-8719(00)00109-X\nSugiyama, Y., Kato, Y. and Ito, K.: Quantitative prediction: metabolism, transport in the liver. in “Preclinical and clinical evaluation of drug-drug interactions” Vol II in Advances in drug development. ISE Press, Inc. in press.\nSugiyama, 2001, Characterization of the efflux transport of 17β-estradiol-D-17β-glucuronide from the brain across the blood–brain barrier, J. Pharmacol. Exp. Ther., 298, 316\nHasegawa, 2002, Functional involvement of rat organic anion transporter 3 (rOAT3) in the renal uptake of organic anions, J. Pharmacol. Exp. Ther., 300, 746, 10.1124\u002Fjpet.300.3.746\nNagata, 2002, Expression and functional characterization of rat organic anion transporter 3 (Slc22a8) in the choroids plexus, Mol. Pharmacol., 61, 982, 10.1124\u002Fmol.61.5.982\nBoyd, 2000, Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion, J. Clin. Pharmacol., 40, 91, 10.1177\u002F00912700022008612\nMalingre, 2001, Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel, J. Clin. Oncol., 19, 1160, 10.1200\u002FJCO.2001.19.4.1160\nMeerum Terwogt, 1999, Coadministration of oral cyclosporin A enables oral therapy with paclitaxel, Clin. Cancer. Res., 5, 3379\nSiedlik, 1999, Erythromycin coadministration increases plasma atorvastatin concentrations, J. Clin. Pharmacol., 39, 501, 10.1177\u002F009127009903900510\nFreeman, 1987, Cyclosporin-erythromycin interaction in normal subjects, Br. J. Clin. Pharmacol., 23, 776\nGupta, 1988, Erythromycin enhances the absorption of cyclosporin, Br. J. Clin. Pharmacol., 25, 401, 10.1111\u002Fj.1365-2125.1988.tb03320.x\nGupta, 1989, Cyclosporin-erythromycin interaction in renal transplant patients, Br. J. Clin. Pharmacol., 27, 475, 10.1111\u002Fj.1365-2125.1989.tb05396.x\nDavit, 1999, FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: Impact on labeling, J. Clin. Pharmacol., 39, 899, 10.1177\u002F00912709922008515\nGrub, 2001, The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients, Eur. J. Clin. Pharmacol., 57, 115, 10.1007\u002Fs002280100277\nFloren, 1997, Tacrolimus oral bioavailability doubles with coadministration of ketoconazole, Clin. Pharmacol. Ther., 62, 41, 10.1016\u002FS0009-9236(97)90150-8\nWestphal, 2000, Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein, Clin. Pharmacol. Ther., 68, 6, 10.1067\u002Fmcp.2000.107579\nGramatte, 1999, Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil, Clin. Pharmacol. Ther., 66, 239, 10.1016\u002FS0009-9236(99)70031-7\nHamman, 2001, The effect of rifampin administration on the disposition of fexofenadine, Clin. Pharmacol. Ther., 69, 114, 10.1067\u002Fmcp.2001.113697\nHebert, 1999, Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers, J. Clin. Pharmacol., 39, 91, 10.1177\u002F00912709922007499\nWestphal, 2000, Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug-drug interaction, Clin. Pharmacol. Ther., 68, 345, 10.1067\u002Fmcp.2000.109797",{"EN":1625},"Drug Transporters: Their Role and Importance in the Selection and Development of New Drugs",{"VOID":1627},"10.2133\u002Fdmpk.17.93","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS1347436715309216",[1630,1645],{"id":1631,"sortIndex":144,"researcher":18,"roles":1632,"affiliations":1633,"properties":1642},"c7858c45-3b5f-4dd9-91bc-9cfefa995d33",[183],[1634],{"id":18,"sortIndex":19,"affiliation":1635,"properties":18},{"id":1636,"createTime":1637,"updateTime":1637,"relativeEntities":1638,"slug":18,"properties":1639,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"afe72e4a-0b8b-4705-9a93-7ebc24926ae5","2024-01-08T23:41:58.689+00:00",[],{"title":1640},{"VI":1641},"Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo-ku, Tokyo, Japan",{"title":1643},{"VI":1644},"Yuichi Sugiyama",{"id":1646,"sortIndex":19,"researcher":18,"roles":1647,"affiliations":1648,"properties":1657},"28c3e5ec-306f-4f2b-98d7-f969ba020041",[183],[1649],{"id":18,"sortIndex":19,"affiliation":1650,"properties":18},{"id":1651,"createTime":1652,"updateTime":1652,"relativeEntities":1653,"slug":18,"properties":1654,"entityType":55,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"58bc49a2-7e6c-4dca-90aa-b0399e95ee7e","2024-01-08T23:41:58.680+00:00",[],{"title":1655},{"VI":1656},"Pharmacokinetics Laboratory, Mitsubishi Pharma, Co., Kisarazu-shi, Chiba, Japan",{"title":1658},{"VI":1659},"Naomi Mizuno",{"url":1628,"publisher":1661,"properties":1688},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1662,"slug":10,"properties":1663,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":1666,"manageAffiliations":1667,"indexDatabases":1668,"url":18,"thumbnailPath":18,"statistic":1683,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":1664,"title":1665},{"VOID":13},{"EN":15},[],[],[1669,1676],{"id":70,"indexDatabase":1670,"url":85,"indexYears":18,"academicFieldIds":1675,"indexDatabaseRanking":18},{"id":72,"createTime":73,"updateTime":74,"relativeEntities":1671,"label":1672,"description":1673,"key":81,"publicationTags":1674,"standard":18},[],{"EN":77,"VI":77},{"VI":79,"EN":80},[83,84],[87],{"id":89,"indexDatabase":1677,"url":102,"indexYears":103,"academicFieldIds":1682,"indexDatabaseRanking":108},{"id":91,"createTime":92,"updateTime":93,"relativeEntities":1678,"label":1679,"description":1680,"key":99,"publicationTags":1681,"standard":18},[],{"EN":96,"VI":96},{"EN":96,"VI":98},[101],[105,106,107],{"impactFactor":19,"impactFactorByYear":1684,"i10Index":116,"i10IndexLast5Year":19,"totalPublication":117,"totalPublicationByYear":1685,"totalCitation":132,"totalCitationByYear":1686,"totalCitationPerPublication":145,"totalCitationPerPublicationByYear":1687,"hindexLast5Year":116,"hindex":116},{"2012":111,"2013":112,"2014":113,"2015":114,"2019":115},{"2002":119,"2003":120,"2004":121,"2005":121,"2006":122,"2007":119,"2008":119,"2009":123,"2010":124,"2011":124,"2012":125,"2013":126,"2014":127,"2015":123,"2016":124,"2017":128,"2018":129,"2019":129,"2020":127,"2021":125,"2022":130,"2023":131,"2024":56},{"2003":134,"2004":135,"2005":136,"2006":137,"2007":138,"2008":139,"2009":140,"2011":141,"2012":142,"2013":143,"2018":144},{"2003":147,"2004":148,"2005":149,"2006":150,"2007":151,"2008":152,"2009":153,"2011":154,"2012":151,"2013":155,"2018":156},{"volume":1689,"pages":1691},{"VOID":1690},"17",{"VOID":1692},"93-108","2002-01-01",2002]